Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT02481830	Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer	CheckMate331	Active, not recruiting	No Results Available	Lung Cancer	Drug: Nivolumab|Drug: Topotecan|Drug: Amrubicin	Overall survival (OS) in subjects with relapsed SCLC|Progression free survival (PFS)|Objective response rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	803	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-331|2015-001097-18	August 28, 2015	August 17, 2018	November 30, 2019	June 25, 2015	null	November 20, 2018	Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Broome Oncology, Johnson City, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Graz, Austria|Local Institution, Wels, Austria|Akh Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Brest, France|Local Institution, Lille Cedex, France|Local Institution, Paris Cedex 14, France|Local Institution, Pringy Cedex, France|Local Institution, Reims, France|Local Institution, Toulon Cedex, France|Local Institution, Bamberg, Germany|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gera, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Immenstadt, Germany|Local Institution, Koeln, Germany|Local Institution, Muenchen, Germany|Local Institution, Oberhausen, Germany|Local Institution, Regensburg, Germany|University Hospital Of Heraklion, Heraklion, Creta, Greece|Sotiria General Hospital, Athens, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Orsz.Koranyi Tbc es Pulm.Int., Budapest, Hungary|Pulmonologiai Klinika, Budapest, Hungary|Local Institution, Beer Sheva, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Ramat -Gan, Israel|Ospedale Bellaria-Maggiore, Bologna, Italy|Ospedale Civile Di Livorno, Livorno, Italy|Ospedale San Luca, Lucca, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera - Nuovo Ospedale San Gerardo, Monza, Italy|Ospedale Degli Infermi, Rimini, Italy|Azienda Ospedaliera S. Andrea, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai, Osaka, Japan|Local Institution, Kitaadachigun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Wojewodzki Szpital Zespolony W Elblagu, Elblag, Poland|Klinika Onkologii I Radioterapii Am, Gdansk, Poland|Oddzial Onkologiczny, Krakow, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Oddzial Onkologii Klinicznej, Poznan, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Basel, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02481830
2	NCT02538666	An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy	CheckMate 451	Active, not recruiting	No Results Available	Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall Survival (OS)|Progression Free Survival (PFS)|An OS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|A PFS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|Tumor mutation burden (TMB)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1327	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-451|2015-002441-61	September 30, 2015	October 1, 2018	November 20, 2019	September 2, 2015	null	November 6, 2018	Sutter Cancer Center, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Oshawa, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhang, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nantong, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon Cedes 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Augsburg, Germany|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Immenhausen, Germany|Local Institution, Tuebingen, Germany|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bologna, Italy|Local Institution, Messina, Italy|Local Institution, Milan, Italy|Local Institution, Perugia, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Miraflores, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Olsztyn, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Lasi, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02538666
3	NCT03090737	Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer	CheckMate 907	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Nivolumab	Incidence of high grade (Grades 3-4 and Grade 5) treatment-related adverse events|Progression-free Survival (PFS) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall Survival (OS)|Duration of Response (DOR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-907|2016-003731-37	May 26, 2017	August 11, 2020	December 7, 2020	March 27, 2017	null	June 19, 2018	Alabama Oncology, Birmingham, Alabama, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Local Institution, West Covina, California, United States|Cancer Specialists, Llc, Jacksonville, Florida, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Broome Oncology, Johnson City, New York, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Cancer Centre Of Southeastern Ontario At Kgh, Kingston, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Debrecen, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Torokbalint, Hungary|Local Institution, Nagoya, Aichi, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, George, Western CAPE, South Africa		https://ClinicalTrials.gov/show/NCT03090737
4	NCT03048136	A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer	CheckMate 955	Withdrawn	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events|Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events|Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall survival (OS) as defined as the time from first dosing to the date of death|Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-955	March 9, 2018	September 29, 2019	September 29, 2019	February 9, 2017	null	April 17, 2018	Local Institution, San Francisco, California, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Lancaster, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Local Institution, Sayre, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Saint George, Utah, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Montreal, Quebec, Canada|Local Institution, Dresden, Germany|Local Institution, Gauting, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Lima, Peru|Local Institution, Lima, Peru		https://ClinicalTrials.gov/show/NCT03048136
5	NCT02613507	Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer	CheckMate 078	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Docetaxel	Overall survival|Objective Response Rate (ORR)|Progression Free Survival (PFS),|Rate of Disease-related Symptom Improvement:	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	644	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-078|2015-001893-16	December 10, 2015	September 15, 2017	January 15, 2019	November 24, 2015	null	May 1, 2018	Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Hong Kong, Hong Kong|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02613507
6	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	CheckMate 498	Recruiting	No Results Available	Brain Cancer	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy	Overall survival (OS)|Progression free survival (PFS)|Overall survival	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	550	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-498|2015-003739-37	February 29, 2016	March 10, 2019	October 1, 2019	December 1, 2015	null	November 20, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Bron Cedex, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt am Main, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Onsen-gun, Ehime, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02617589
7	NCT02574078	A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)	CheckMate370	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Bevacizumab|Drug: Pemetrexed|Other: Best Supportive Care|Drug: nab-Paclitaxel|Drug: Paclitaxel|Drug: Docetaxel|Drug: Gemcitabine|Drug: Erlotinib|Drug: Crizotinib|Drug: Carboplatin	Group A: Progression-free survival (PFS)|Group A: Overall survival (OS)|Group B: Progression-free survival (PFS)|Group B: Overall survival (OS)|Group C: Progression-free survival (PFS)|Group C: Overall survival (OS)|Group D: Progression-free survival (PFS)|Group E: Number of Incidence of treatment-related Adverse events (AEs) leading to both study drugs discontinuation|Group A: Duration of response (DOR)|Group A: Objective Response rate (ORR)|Group B: Duration of response (DOR)|Group B: Objective Response rate (ORR)|Group C: Duration of response (DOR)|Group C: Objective Response rate (ORR)|Group D: Overall survival(OS)|Group D: Duration of response (DOR)|Group D: Objective Response rate (ORR)|Group E: PFS|Group E: ORR	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	342	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-370	November 13, 2015	April 15, 2019	April 15, 2019	October 12, 2015	null	May 2, 2018	Alabama Oncology, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|Scripps Cancer Center, La Jolla, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Solvang, California, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University of Florida at Shands, Gainesville, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Florida Cancer Affiliates, Trinity, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cotton-O-Neil Clinical Research Center, Topeka, Kansas, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus St. Francis Cabrini Cancer Center, Alexandria, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University Of Maryland, Baltimore, Maryland, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Summit Medical Group, Morristown, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Morristown Medical Center, Summit, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Broome Oncology, Johnson City, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|White Plains Hospital, White Plains, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Moses Cone Health System, Greensboro, North Carolina, United States|Randolph Cancer Center, Greensboro, North Carolina, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Cancer Care Center, Bismarck, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Hematology Oncology Associates, Medford, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Erie Regional Cancer Center, Erie, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Sanford Research, Sioux Falls, South Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology/Methodist Charlton Cancer Ctr, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|Texas Oncology, El Paso, Texas, United States|Texas Oncology, Flower Mound, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Investigational Products Ctr, Irving, Texas, United States|Texas Cancer Center Of Mesquite, Mesquite, Texas, United States|Texas Oncology, Pa, Midland, Texas, United States|Texas Oncology, New Braunfels, Texas, United States|Texas Oncology, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Plano West Cancer Center, Plano, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Texas Oncology, P.A., Webster, Texas, United States|Texas Oncology, Weslaco, Texas, United States|Texas Oncology-Wichita Falls, Wichita Falls, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Blacksburg, Virginia, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, Pc, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States		https://ClinicalTrials.gov/show/NCT02574078
8	NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	CheckMate649	Recruiting	No Results Available	Gastric Cancer|Gastroesophageal Junction Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Leucovorin|Drug: Fluorouracil	Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants|Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants|OS in all randomized participants|PFS, as assessed by BICR, in all randomized participants|Objective Response Rate (ORR), as assessed by BICR, in all randomized participants|Time to symptom deterioration (TTSD) of nivolumab + ipilimumab vs oxaliplatin + fluoropyrimidine in all randomized participants	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1649	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-649|2016-001018-76	October 4, 2016	March 28, 2021	October 6, 2022	August 19, 2016	null	November 6, 2018	Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology, Texas Cancer Center At Medical City, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Blacktown Hospital, Blacktown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico de la Universidad De Chile, Independencia, Santiago, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|ICOS - Inmunomedica, Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Hangzhou, China|Local Institution, Tianjin, China|Local Institution, Bogota, Cundinamarca, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Local Institution, Pasto, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Plerin, France|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Of Cologne, Cologne, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaets-Krankenhaus Eppendorf, Hamburg, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Rechts Der Isar, Muenchen, Germany|Laiko General Hospital Of Athens, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|University General Hospital of Patras, Patras, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|ASST Papa Giovanni XXIII, Bergamo, Italy|Local Institution, Firenze, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Osp. Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Queretaro, Mexico|Clinica Anglo Americana, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Clinica Internacional sede San Borja, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Local Institution, Nowy Sacz, Poland|Centrum Onkologiczne: Oddzial Onkologii Klinicznej oraz Poradnia Onkologiczna, Tarnobrzeg, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Baia Mare, JUD Maramures, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Badajoz, Spain|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02872116
9	NCT02985957	A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer	CheckMate 650	Active, not recruiting	No Results Available	Prostate Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Radiographic Progression-Free Survival (rPFS)|Radiographic/Clinical Progression-Free Survival (rcPFS)|Overall Survival (OS)|Number of patients with adverse events|Number of patients with serious adverse events|Number of patients with adverse events leading to discontinuation|Number of patients with immune-mediated adverse events|Number of patients with deaths|Number of patients with laboratory abnormalities|Number of patients with changes in pain as measured by Brief Pain Inventory-Short Form (BPI-SF)|European Quality of Life- Five Dimensions (EQ-5D-3L) scores	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-650|2016-001928-54	March 17, 2017	December 16, 2018	March 24, 2022	December 7, 2016	null	June 19, 2018	University of Chicago, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT02985957
10	NCT03195491	A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia	CheckMate870	Active, not recruiting	No Results Available	Lung Cancer|Non-Small Cell Lung Cancer	Biological: Nivolumab	Incidence of high grade treatment-related select adverse events in non-hepatitis B virus (HBV) infected participants|Severity of high grade treatment-related select adverse events in non-HBV infected participants|Incidence of high grade treatment-related select adverse events in HBV infected participants|Severity of high grade treatment-related select adverse events in HBV infected participants|Laboratory test abnormalities|Incidence of adverse events in all treated patients|Severity of adverse events in all treated patients	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	400	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-870	December 19, 2017	January 15, 2019	July 29, 2022	June 22, 2017	null	September 26, 2018	Local Institution, Dallas, Texas, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Beijing, Hebei, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Zhengzhou, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Jinan City, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Wulumuqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Shenyang, China|Local Institution, Bangkok, Thailand|Local Institution, Khon Kaen, Thailand		https://ClinicalTrials.gov/show/NCT03195491
11	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer	CheckMate 9KD	Recruiting	No Results Available	Prostate Cancer	Biological: Nivolumab|Drug: Docetaxel|Drug: Enzalutamide|Drug: Rucaparib|Drug: Prednisone	Objective Response Rate (ORR)|Prostate-specific antigen response rate (RR-PSA)|Radiographic progression-free survival (rPFS)|Time to response (TTR)|Duration of response (DOR)|Time to prostate-specific antigen progression (TTP-PSA)|Overall Survival (OS)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)	Bristol-Myers Squibb|Clovis Oncology|Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Phase 2	330	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9KD	December 15, 2017	February 18, 2020	November 18, 2020	November 9, 2017	null	November 12, 2018	Southern Cancer Center Pc, Daphne, Alabama, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Local Institution, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Amsterdam, New York, United States|Local Institution, New York, New York, United States|Duke University, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Santa Catarina, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|BC Cancer - Kelowna, Kelowna, British Columbia, Canada|Local Institution, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Local Institution, Saint John, New Brunswick, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Besancon, France|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Uniklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Praxisklinik Fuer Haematologie Und Onkologie, Koblenz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Leon, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03338790
12	NCT02713867	A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	CheckMate 384	Active, not recruiting	No Results Available	Lung Cancer	Biological: Nivolumab	Progression Free Survival (PFS) rate at 6 months after randomization|Progression Free Survival (PFS) rate at 12 months after randomization|Progression Free Survival (PFS) rate by tumor histology and by response criteria|Progression Free Survival (PFS) rate|Overall Survival Rate (OSR)|Safety and Tolerability assessed by the incidence and severity of adverse events (AEs)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	350	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-384	April 21, 2016	June 30, 2022	June 30, 2022	March 21, 2016	null	September 17, 2018	Alabama Oncology, Birmingham, Alabama, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncology Associates PC - NAHOA, Phoenix, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Southern California Permanente Medical Group, Bellflower, California, United States|St Jude Hospital Yorba Linda, Fullerton, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|Rocky Mountain Cancer Centers Llp, Lone Tree, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ocala Oncology Center, Pl, Ocala, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|Ingalls Health System, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Illinois Cancercare, Pc, Peoria, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Innova Schar Cancer Institute, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Cancer Care Of Maine, Brewer, Maine, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|Providence Cancer Center, Southfield, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|North Mississippi Med Center, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|Broome Oncology, Johnson City, New York, United States|First Health Of The Carolinas, Pinehurst, North Carolina, United States|Hematology And Oncology Associates, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Cancer Care Center, Cleveland, Ohio, United States|Tri-County Hematology & Oncology Associates, Inc, Massillon, Ohio, United States|Hematology Oncology Consultants, Pc, Medford, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Texas Oncology, P.A., El Paso, Texas, United States|Texas Oncology, P.A., Flower Mound, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Texas Oncology, P.A., Longview, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, P.A., Plano, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology, P.A., Sherman, Texas, United States|Texas Oncology, P.A., Sugar Land, Texas, United States|Texas Oncology, Wichita Falls, Texas, United States|Innova Schar Cancer Institute, Falls Church, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Local Institution, St. Leonards, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Wien, Austria|Local Institution, Newmarket, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bayonne, France|Local Institution, Clermont-Ferrand, France|Local Institution, Le Mans, France|Local Institution, Mulhouse, France|Local Institution, Nimes, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pontoise, France|Local Institution, Suresnes, France|Local Institution, Tours, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Villefranche-sur-Saone, France|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Freiburg, Germany|Local Institution, Gauting, Germany|Local Institution, Greifenstein, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Lostau, Germany|Local Institution, Moers, Germany|Local Institution, Nurnberg, Germany|Local Institution, Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, El Palmar, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Sabadell-Barcelona, Spain|Local Institution, Seville, Spain		https://ClinicalTrials.gov/show/NCT02713867
13	NCT03414983	An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread	CheckMate 9X8	Recruiting	No Results Available	Colorectal Cancer	Biological: Nivolumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Bevacizumab	Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Time to Response (TTR)|Overall Survival (OS)|Number of Adverse Events ( AEs)|Number of Serious Adverse Events ( SAEs)|Number of deaths|Number of clinical abnormalities	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9X8|2017-003662-27	February 14, 2018	August 16, 2021	August 18, 2022	January 30, 2018	null	November 20, 2018	Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, San Diego, California, United States|Local Institution, Santa Barbara, California, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Baptist Health Medical Group, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Henderson, Nevada, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Ctr at NYU Langone, New York, New York, United States|Local Institution, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Sanford Research, Sioux Falls, South Dakota, United States|Local Institution, Chattanooga, Tennessee, United States|Local Institution, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Tyler, Longview, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Virginia Cancer Center, Richmond, Virginia, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain		https://ClinicalTrials.gov/show/NCT03414983
14	NCT03001882	An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	CheckMate 592	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Objective Response Rate (ORR) of patient subgroups defined by baseline biomarkers|Disease Control Rate (DCR) of patient subgroups defined by baseline biomarkers|Duration of Response (DOR) of patient subgroups defined by baseline biomarkers|Time to Response (TTR) of patient subgroups defined by baseline biomarkers|Progression Free Survival (PFS) of patient subgroups defined by baseline biomarkers|Overall Survival (OS) of patient subgroups defined by baseline biomarkers|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-592|2018-000462-11	March 14, 2017	September 28, 2021	December 14, 2021	December 23, 2016	null	November 20, 2018	Highland Oncology Group, Fayetteville, Arkansas, United States|Yale University, New Haven, Connecticut, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Bronx, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Gent, Belgium|Local Institution, Gent, Belgium|Local Institution, Haine Saint Paul, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Pierre Benite, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon, France|Klinik Essen-Mitte, Essen, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Local Institution, Lowenstein, Germany|Klinikum Stuttgart, Stuttgart, Germany|ASST Papa Giovanni XXIII, Bergamo, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera Di Perugia, Perugia, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Instituto Catalan De Oncologia, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03001882
15	NCT02659059	Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	CheckMate 568	Active, not recruiting	No Results Available	Non-Small-Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Platinum Doublet Chemotherapy	Objective response rate (ORR)|ORR|Number of Patients with dose Limiting Toxicities (DLTs)|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Deaths|Number of Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE)|Progression free survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	507	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-568	February 10, 2016	November 6, 2018	April 20, 2022	January 20, 2016	null	September 19, 2018	Sharp Memorial Hospital, San Diego, California, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Cleveland Clinic Florida, Weston, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Mexico Hematology Oncology Consultants, Albuquerque, New Mexico, United States|Lovelace Cancer Care, Albuquerque, New Mexico, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center, Albuquerque, New Mexico, United States|The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Csss De St-Jerome, St.Jerome, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02659059
16	NCT02477826	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	CheckMate 227	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Paclitaxel	Overall survival (OS)|Progression-free Survival (PFS) as determined by blinded independent central review (BICR)|Objective response rate (ORR)|Disease related symptom improvement as measured by the Lung Cancer Symptom Score (LCSS) in all subjects	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	2220	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-227|2014-003630-23	August 5, 2015	January 31, 2019	December 31, 2020	June 23, 2015	null	November 29, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02477826
17	NCT02409368	An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC	Checkmate 171	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab	Incidence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in subjects with advanced or metastatic SqNSCLC|Incidence and to characterize the outcome of all high-grade (CTCAE v4.0 Grades 3-4), select adverse events|Overall survival (OS) in all treated subject|Investigator-assessed objective response rate (ORR)|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events	Bristol-Myers Squibb|PPD	All	18 Years and older   (Adult, Older Adult)	Phase 2	800	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA209-171|2014-001285-10	April 23, 2015	September 15, 2019	December 24, 2019	April 6, 2015	null	October 3, 2018	Southampton University Hospitals NHS Trust, Raleigh, North Carolina, United States|Local Institution, Salzburg, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense C, Denmark|Local Institution, Oulu, Finland|Local Institution, Pori, Finland|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Heraklion, Greece|Local Institution, Rio, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Instytut Medyczny Santa Familia Sp. z o.o., Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Zabrze, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Oradea, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Burgos, Spain|Local Institution, Granada, Spain|Local Institution, La Laguna, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Solna, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Bristol, United Kingdom|Local Institution, Cardiff, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|North Middlesex Hospital, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Plymouth, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02409368
18	NCT02066636	A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen	CheckMate153	Active, not recruiting	No Results Available	Non Small Cell Lung Cancer (NSCLC)	Drug: Nivolumab	Incidence for high grade (Grade 3-4 and Grade 5) treatment related select adverse events (AEs)|Incidence for high grade (Grade 3-4 and Grade 5) select AEs|Median time to onset and median time to resolution (Grade 3-4)|Percentage of subjects who received immune modulating medication or hormonal replacement therapy, percentage of subjects who received ≥40 mg Prednisone equivalents, total duration of all immune modulating medications given for select event	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1380	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-153	February 28, 2014	January 31, 2022	January 31, 2022	February 19, 2014	null	August 14, 2018	Southern Cancer Center Pc, Mobile, Alabama, United States|Cancer Center Treatment Center of America, Goodyear, Arizona, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates, Sedona, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|Diablo Valley Oncology, Concord, California, United States|Saint Jude Heritage Medical Group Virginia K Crosson Cancer Center, Fullerton, California, United States|Ucla Hema/Onc-Santa Monica, Los Angeles, California, United States|Torrance Memorial Medical Center, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Pacific Cancer Care, Salinas, California, United States|Local Institution, San Francisco, California, United States|Central Coast Med Oncology, San Luis Obispo, California, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Ct Hem Onc Assoc, Norwich, Connecticut, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Watson Clinic Center For Research,Inc, Lakeland, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Sacred Heart Medical Oncology Group, Pensacola, Florida, United States|Hematology/Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Space Coast Cancer Center, Titusville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Central Georgia Cancer Care, Pc, Macon, Georgia, United States|Cancer Treatment Centers Of America, Newnan, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Pearlman Cancer Center, Valdosta, Georgia, United States|University Of Illinois Cancer Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Southern Illinois University School Of Medicine, Springfield, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Center, Louisville, Kentucky, United States|University Medical Center, Inc, Louisville, Kentucky, United States|West KY Hematology Oncology Group PSC, Paducah, Kentucky, United States|Christus Schumpert Health, Shreveport, Louisiana, United States|Local Institution, Brewer, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Walter Reed National Mltry Medical Center, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Bay Hematology Oncology, Easton, Maryland, United States|Michigan Cancer Research Consortinum, Ann Arbor, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Providence Cancer Center, Southfield, Michigan, United States|Forrest General Cancer Center, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|Presbyterian Medical Group, Albuquerque, New Mexico, United States|St. Peters Hospital, Albany, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Kisco Medical Group, Mount Kisco, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Hematology-Oncology Associates Of Rockland, Nyack, New York, United States|Randolph Cancer Center, Asheboro, North Carolina, United States|Cancer Care Of Wnc, Asheville, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center, Greensboro, North Carolina, United States|East Carolina University Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States|Oncology Hematology Care, Incorporated, Cincinnati, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Zangmeister Cancer Center, Columbus, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's University Hospital Bethlehem, Bethlehem, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|Texas Oncology-Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology, Arlington, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, Grapevine, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Texas Oncology, Mesquite, Texas, United States|Texas Oncology - Odessa, Midland, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System., Charlottesville, Virginia, United States|Shenandoah Oncology, Winchester, Virginia, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Levis, Quebec, Canada|Local Institution, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02066636
19	NCT03519256	A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder	CheckMate 9UT	Recruiting	No Results Available	Bladder Cancer|Bladder Tumors|Neoplasms, Bladder	Biological: Nivolumab|Biological: BCG|Drug: BMS-986205	Proportion of carcinoma in situ (CIS) participants with complete response (CR), per Pathology Review Committee (PRC)|Duration of complete response (DOCR), per PRC, in CIS participants with CR|Event Free Survival (EFS), per PRC, for all non-CIS participants|Progression-free Survival (PFS)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of AEs leading to discontinuation|Incidence of deaths|Incidence of laboratory abnormalities	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	436	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9UT|2017-003581-27	May 25, 2018	January 4, 2022	April 16, 2023	May 8, 2018	null	November 20, 2018	Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Local Institution, Riverside, California, United States|Local Institution, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|Local Institution, Westwood, Kansas, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|Adult & Pediatric Urology, Omaha, Nebraska, United States|Local Institution, Voorhees, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Springfield, Oregon, United States|Local Institution, Bala-Cynwyd, Pennsylvania, United States|Local Institution, Hershey, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Virginia Beach, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Campinas, SAN Paulo, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, LILLE Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Suresnes, France|Local Institution, Hong Kong, Hong Kong|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Omsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Lancaster, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT03519256
20	NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread	CheckMate142	Recruiting	No Results Available	Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer	Drug: Ipilimumab|Drug: Nivolumab|Drug: Cobimetinib|Drug: Daratumumab|Drug: anti-LAG-3 antibody	Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators|ORR in all MSI-H and non-MSI-H subjects based on IRRC determination	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	340	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-142|2013-003939-30	March 7, 2014	December 3, 2019	December 30, 2020	February 11, 2014	null	November 20, 2018	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Allina Health System, Minneapolis, Minnesota, United States|Duke University Office of Research Administration, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris, France|Local Institution, Dublin 4, Ireland|Local Institution, Dublin 9, Ireland|Local Institution, Galway, Ireland|Local Institution, Candiolo, TO, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT02060188
21	NCT02743494	An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer	CheckMate 577	Recruiting	No Results Available	Advanced Cancer	Drug: Nivolumab|Other: Placebo	Disease-Free Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall Survival of adjuvant nivolumab in subjects with resected esophageal cancer or gastroesophageal junction cancer who have received chemoradiotherapy followed by surgery|Overall survival rate	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	760	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-577|2015-005556-10	May 23, 2016	September 14, 2020	October 11, 2024	April 19, 2016	null	November 20, 2018	Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Ucsf Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|SCRI Florida Cancer Specialists North, Saint Petersburg, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Mass General/North Shore Cancer Center for Outpatient Care, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Albert Einstein Cancer Center At The Montefiore Medical Park, Bronx, New York, United States|NYU Langone Medical Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Sioux Falls, South Dakota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|Local Institution, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Local Institution, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Aleman, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Fundacion Favaloro, Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Moorabbin Hospital, Clayton, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Namur, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itacorubi, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Local Institution, Ottawa, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Hotel Dieu De Quebec, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Linhai, Zhejiang, China|Local Institution, Changsha, China|Local Institution, Shanghai, China|Local Institution, Tianjin, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Local Institution, Avignon Cedes 9, France|Local Institution, Dijon Cedex, France|Local Institution, LILLE Cedex, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Toulouse, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Local Institution, Hamburg, Germany|University Hospital Of Cologne, Koeln, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Universitaets-Klinikum Marburg, Marburg, Germany|Klinikum Rechts Der Isar, Munich, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-Shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Shinjuuku-ku, Tokyo, Japan|Local Institution, Fukuoka, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Centro de Estudios y Prevencion Del Cancer, AC, Tuxtla Gutierrez, Chiapas, Mexico|Instituto Nacional De Cancerologia, Tlalpan, Distrito Federal C.P., Mexico|Fundacion Rodolfo Padilla Padilla A.C., Leon de los Aldama, Guanajuato, Mexico|Hospital Cardiologica De Aguascalientes, Aguascalientes, Mexico|Supere Centro de Infusion S.A de C.V., Ciudad de Mexico, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Distrito Federal, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Oncosalud Sac, Lima, Peru|Local Institution, Lima, Peru|II Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Oddzial Kliniczny Chirurgii Klatki Piersiowej, Krakow, Poland|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Oddzial Onkologii Klinicznej i Doswiadczalnej, Poznan, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|SC Oncopremium Team SRL, Baia Mare, Romania|Fundeni Clinical Institute Gastroenterology; Hepatology Clin, Bucharest, Romania|Focus Lab Plus SRL, Bucuresti, Romania|Bendis Clinic Srl, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Local Institution, Cheboksary, Russian Federation|Local Institution, Moscow, Russian Federation|N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Saint-Petersburg Medical University Named After I.P.Pavlov, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Universitaetsspital Basel, Basel, Switzerland|Kantonsspital St Gallen, St Gallen, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Baskent University Adana Hospital, Adana, Turkey|Local Institution, Ankara, Turkey|Ataturk University, Erzurum, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Onkoloji, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Cardiff, United Kingdom		https://ClinicalTrials.gov/show/NCT02743494
22	NCT02632409	An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer	CheckMate 274	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Other: Placebo	Disease free survival (DFS)|Non-Urothelial track recurrence free survival (NUTRFS)|Disease specific survival (DSS)|Overall survival (OS)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	640	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA209-274|2014-003626-40	February 11, 2016	April 30, 2020	May 1, 2020	December 16, 2015	null	November 6, 2018	Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University Of California San Francisco-Fresno, Fresno, California, United States|University Of California - Davis, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|University Of Florida, Gainesville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Tulane University, New Orleans, Louisiana, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Fairview Health Services, Burnsville, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina, Chapel Hill, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Northwest Cancer Specialists, Pc, Tualatin, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Local Institution, Virginia Beach, Virginia, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Hospital Britanico De Buenos Aires, Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Local Institution, Frankston, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Salzburger Landeskliniken Lkh, Salzburg, Austria|Akh Wien, Vienna, Austria|AKH Allgemeines Krankenhaus Wien, Wien, Austria|Local Institution, Hasselt, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, S?o Paulo, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|Clinica Alemana de Temuco S.A., Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Fundacion Oftalmologica De Santander - Foscal, Floridablanca, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Local Institution, Aalborg, Denmark|Local Institution, Aarhus C, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Suresnes, France|Local Institution, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinik Essen-Mitte, Essen, Germany|Univ Klinikum Der Ernst-Moritz-Arndt-Univ Greifswald, Greifswald, Germany|Uni Hamburg-Eppendorf, Hamburg, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitatsklinikum Giessen Und Marburg, Marburg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Local Institution, Nuernberg, Germany|Klinikum Der Universitaet Regensburg, Regensburg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Alexandra General Hospital, Athens, Greece|Theagenio Hospital, Thessaloniki, Greece|Local Institution, Wilton, Cork, Ireland|Adelaide And Meath Hospital, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Zerifin, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Local Institution, Pavia, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Arcispedale S. Maria Nuova - A.O. Reggio Emilia, Reggio Emilia, Italy|Istituto Regina Elena, Roma, Italy|Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Instituto Nacional De Cancerologia, Mexico City, Distrito Federal, Mexico|Arke Estudios Clinicos Sa De Cv, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Arequipa, Peru|Clinica Internacional sede San Borja, Lima, Peru|Klinika Onkologii i Radioterapii, Gdansk, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Mazovia Szpital, Warsaw, Poland|Local Institution, Wroclaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|Hospital General Universitari Vall D'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Lund, Sweden|Kantonsspital Basel, Basel, Switzerland|OnkoZentrum Zurich, Zuerich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Cardiff, Cardiganshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Cancer Research Centre, Sheffield, Yorkshire, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02632409
23	NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer	CheckMate901	Recruiting	No Results Available	Urothelial Cancer	Biological: nivolumab|Biological: ipilimumab|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin	Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) of cisplatin-ineligible participants|PFS based on BICR assessment of nivolumab combined with standard of care (SOC) chemotherapy to SOC chemotherapy in cisplatin-ineligible participants with previously untreated, unresectable or metastatic Urothelial Cancer (UC)|Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) in all participants|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Global Health Status score|OS in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC.	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	897	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-901|2016-003881-14	March 24, 2017	April 26, 2020	December 23, 2022	January 30, 2017	null	November 6, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Local Institution, Little Rock, Arkansas, United States|VA of Central California Health Care System, Fresno, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Local Institution, Iowa City, Iowa, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Milford Regional Medical Center, Boston, Massachusetts, United States|South Shore Hospital Cancer Center, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Ridges Cancer Clinic, Burnsville, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Nh Hematology - Oncology, Hooksett, New Hampshire, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Local Institution, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Kirkland, Washington, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Tugun, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Doubleview, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Vitacura, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 9, France|Local Institution, Nimes Cedex 09, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Suresnes, France|Local Institution, Tours Cedex, France|Local Institution, Villejuif, France|Universitat Dresden, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Local Institution, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Kliniken Nordoberpfalz AG, Weiden, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Kfar Saba, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale Per Gli Infermi, Faenza, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Forli, Italy|Ospedale Della Misericordia Grosseto, Grosseto, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kita-Gun, Kagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Arakawa-ku,tokyo, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Ube City, Yamaguchi, Japan|Local Institution, Goyang-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Centro Universitario Contra el Cancer UANL, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica El Golf, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Koszalin, Poland|Klinika Nowotworow Ukladu Moczowego Centrum Onkologii - Inst, Warszawa, Poland|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Comp. Hosp. Univ. A Coruna, A Coruna, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Jonkoping, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Lund, Sweden|Kantonsspital Baden, Baden, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey		https://ClinicalTrials.gov/show/NCT03036098
24	NCT02593786	A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors	CheckMate 077	Recruiting	No Results Available	Solid Tumors	Drug: Nivolumab	Safety measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Tolerability measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations|Objective response rate (ORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-077	December 25, 2015	October 8, 2019	October 8, 2019	November 2, 2015	null	October 4, 2018	Local Institution, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT02593786
25	NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	CheckMate548	Recruiting	No Results Available	Brain Neoplasms	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo	Overall survival (OS) defined as time from the date of randomization to the date of death.|Progression free survival (PFS), defined as the time from randomization to the date of the first documented tumor progression or death to any cause.|Correlation of PFS and OS	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	693	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA209-548|2015-004722-34	May 5, 2016	February 11, 2022	August 1, 2023	January 29, 2016	null	October 23, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Local Institution, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 03, France|Local Institution, Marseille, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinik Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Bezirksklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kyoto, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02667587
26	NCT02832167	An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread	CheckMate 627	Recruiting	No Results Available	Cancer	Biological: Nivolumab	Objective Response Rate (ORR) as determined by investigator|Overall Survival (OS) is defined as the time from the first dosing date to the date of death|Duration of clinical response|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Clinical Benefit Rate (CBR) defined as the number of participants with a best overall response of confirmed complete response (CR) or partial response (PR), or stable disease divided by the number of all treated participants|Time to Response (TTR) defined as the time from first dosing date to the date of the first confirmed response, as assessed by investigator|Programmed death-ligand 1 (PD-L1) expression as determined by biomarker analysis|MisMatch Repair (MMR) alterations as determined by biomarker analysis	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-627|2016-000461-23	September 13, 2016	June 16, 2019	December 20, 2019	July 14, 2016	null	May 22, 2018	Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|LACN, Los Angeles, California, United States|UCLA Main Campus - University California Los Angeles, Los Angeles, California, United States|Torrence Health Association, DBA Torrance Memorial;Physician Network/Cancer Care Associates, Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|St. Mary's Hospital And Regional Medical Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Memorial Healthcare System, Hollywood, Florida, United States|Florida Cancer Affiliates, Ocala, Florida, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Maryland Oncology Hematology P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Research Medical Center, Kansas City, Missouri, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Hematology Oncology Associates, PC, Medford, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|Greenville Health System, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Baylor Charles A. Simmons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology, P.A., San Antonio, Texas, United States|Texas Oncology The Woodlands, The Woodlands, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Freiburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munchen, Germany		https://ClinicalTrials.gov/show/NCT02832167
27	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread	CheckMate9N9	Recruiting	No Results Available	Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm	Biological: Nivolumab|Drug: Trametinib|Biological: Ipilimumab	Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Time to response (TTR)|Progression free survival (PFS)|Overall survival (OS)	Bristol-Myers Squibb|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	345	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9N9|2017-001830-24	January 22, 2018	September 21, 2021	November 24, 2022	December 19, 2017	null	October 9, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Local Institution, Fort Collins, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Durham, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Cologne, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heilbronn, Germany|Local Institution, Mannheim, Germany|Local Institution, Munich, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Aberdeen, Aberdeenshire, United Kingdom|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03377361
28	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)	CheckMate 816	Recruiting	No Results Available	Non Small Cell Lung Cancer	Biological: Nivolumab|Biological: ipilimumab|Drug: cisplatin|Drug: vinorelbine|Drug: gemcitabine|Drug: docetaxel|Drug: pemetrexed|Drug: carboplatin	Event-Free Survival|Pathological Complete Response|Overall survival (OS)|Major pathological response (MPR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	642	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-816|2016-003536-21	January 13, 2017	May 8, 2023	November 8, 2028	December 20, 2016	null	October 3, 2018	Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|HOPE Cancer Center of East Texas, Phoenix, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Santa Rosa, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|University of Miami, Deerfield Beach, Florida, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Jacksonville, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Orlando, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Local Institution, Athens, Georgia, United States|Local Institution, Fort Gordon, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Tinley Park, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Elizabethtown, Kentucky, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Medstar Franklin Sqaure Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Fairhaven, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Local Institution, Columbia, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Valley Hospital Luckow Pavili, Westwood, New Jersey, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, High Point, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Genesis Health Care System, Zanesville, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|WBAMC Oncology Department, El Paso, Texas, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology, Waco, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Vermont Cancer Center, Burlington, Vermont, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Local Institution, Fredericksburg, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, MG, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ijui, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|CISSS de l'Outaouais, Gatineau, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Mcgill University Health Center, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Shanghai, China|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Tours Cedex, France|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kitakyushu-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT02998528
29	NCT02475382	Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen	CheckMate 169	No longer available	No Results Available	Squamous Non-Small Cell Lung Cancer|Non-squamous Non-Small Cell Lung Cancer	Drug: Nivolumab		Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)		null	Industry	Expanded Access		CA209-169	null	null	null	June 18, 2015	null	July 26, 2017	Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Cascavel, Parana, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Recife, Pernambuco, Brazil|Local Institution, Recife, Pernambuco, Brazil|Local Institution, Natal, Rio Grande Do Norte, Brazil|Local Institution, Ijui, Rio Grande do Sul, Brazil|Local Institution, Passo Fundo, Rio Grande do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Ribeirao Preto, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Distrito Federal, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Burnaby, British Columbia, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Richmond, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Chicoutimi, Quebec, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02475382
30	NCT03215706	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC	CheckMate 9LA	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Ipilimumab|Biological: Nivolumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|ORR|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9LA|2017-001195-35	July 20, 2017	August 25, 2019	May 20, 2020	July 12, 2017	null	November 29, 2018	Memorial Health Systems, Colorado Springs, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, LaGrange, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Ohio State University, Columbus, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Natal, RIO Grande DO Norte, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Amiens Cedex 1, France|Local Institution, Caen, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Saint-Brieuc, France|Local Institution, Berlin, Germany|Asklepios Fachkliniken Munchen-Gauting Thorakale Onkologie, Gauting, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Fachklinik Fuer Lungenkrankheiten, Immenhausen, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Ospedale San Luca, Lucca, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Monaldi, Napoli, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Himeji-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Oncotech, La Paz, BAJA Californa SUR, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Faicic S. de Rl. de Cv, Veracruz, Veracruz, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Onkologii, Bytom, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Carlos Haya De Malaga, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Tauton, United Kingdom		https://ClinicalTrials.gov/show/NCT03215706
31	NCT01673867	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC	CheckMate057	Active, not recruiting	Has Results	Non-Squamous Cell Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|One-year Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) Rate at 12 Months|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	792	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-057|2012-002472-14	October 10, 2012	February 5, 2015	December 21, 2018	August 28, 2012	February 26, 2016	April 10, 2018	Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|City Of Hope, Duarte, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Winthrop University Hospital Oncology/Hematology, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Clinic, Ltd, Sayre, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Columbia Basin Hematology And Oncology, Kennewick, Washington, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad De Buenos Aires, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Tweed Heads, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Centre De Sante Et De Services Sociaux Rimouski Neigette, Rimouski, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Praha 8, Czechia|Local Institution, Creteil, France|Local Institution, Dijon Cedex, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Mainz, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Parma, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Oslo, Norway|Local Institution, Miraflores, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Vizcaya, Spain|Local Institution, Chur, Graubuenden, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Chur, Switzerland		https://ClinicalTrials.gov/show/NCT01673867
32	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies	CheckMate 908	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose limiting toxicity (DLT)|Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs)|Overall Survival (OS)|Progression Free Survival (PFS)|Incidence of AEs|Incidence of SAEs|Incidence of laboratory abnormalities|Overall Survival|Progression Free Survival	Bristol-Myers Squibb	All	6 Months to 21 Years   (Child, Adult)	Phase 2	170	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-908|2016-004441-82	June 6, 2017	June 14, 2021	June 15, 2021	April 27, 2017	null	September 11, 2018	Children's Hospital Of Los Angeles, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Children'S Hospital, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Mcknight Brain Institute, Gainesville, Florida, United States|Children'S Memorial Hospital, Chicago, Illinois, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|The Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Jude Children'S Research Hospital, Memphis, Tennessee, United States|Baylor College Of Medicine, Houston, Texas, United States|Local Institution, Randwick, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ribeirao Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, VIillejuif, France|Universitaetsklinik Essen, Essen, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Hopp Children?s Cancer Center at NCT Heidelberg, Heidelberg, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Erasmus Mc , Locatie Sophia, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Local Institution, Oslo, Norway|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Solna, Sweden|Great Ormond Street Hospital For Children, London, Greater London, United Kingdom|Alder Hey Children'S Hospital, Liverpool, Merseyside, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Birmingham, United Kingdom		https://ClinicalTrials.gov/show/NCT03130959
33	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	CheckMate358	Recruiting	No Results Available	Various Advanced Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Relatlimab|Drug: Daratumumab	The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)|Objective response rate|Rate of surgery delay|Progression-free survival|Overall survival|Duration of response	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-358|2015-000230-29	October 8, 2015	May 13, 2019	December 31, 2019	July 2, 2015	null	October 19, 2018	H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Local Institution, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Desc. Med Ctr, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center-Breast Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Sanford Clinic Clinical Research, Sioux Falls, South Dakota, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Oaxaca de Juarez, Oaxaca, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Craiova, Romania|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Clinica Universitaria De Navarra, Navarra, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02488759
34	NCT02823574	Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 714	Active, not recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall response rate (ORR) in platinum refractory subgroup|Duration of Response (DOR) in platinum refractory subgroup|ORR in platinum eligible subgroup|Progression Free Survival (PFS) in platinum eligible and refractory subgroups|Overall Survival (OS) in platinum eligible and refractory subgroups|DOR in platinum eligible subgroup|Tumor mutation burden (TMB) in platinum eligible and refractory subgroups	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-714|2016-001645-64	September 22, 2016	January 30, 2019	January 30, 2024	July 6, 2016	null	November 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Ucsf, San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|University Of Louisville, Louisville, Kentucky, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mission Hospital, Inc, Asheville, North Carolina, United States|University Of Cincinnati Medical School, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|UPMC, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University Of Washington, Seattle, Washington, United States|Centro de Investigacion Pergamino SA- Clinica Pergamino, Pergamino, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Buenos Aires, Argentina|Universitair Ziekenhuis Gent, Gent, Belgium|Az Nikolaas, Sint-Niklaas, Belgium|Ucl Mont-Godinne, Yvoir, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Caxias do Sul, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Santo Andre, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute., Edmonton, Alberta, Canada|The Ottawa General Hospital, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval - Hopital de l'Enfant Jesus, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Helsinki University Hospital, Helsinki, Finland|Chu Amiens - Groupe Hospitalier Sud, Amiens Cedex 1, France|Local Institution, Bordeaux, France|Centre Jean Perrin, Clermont Ferrand cedex 01, France|Local Institution, Clichy, France|Centre Leon Berard, Lyon Cedex 08, France|Hopital De La Timone, Marseille Cedex 5, France|Local Institution, Nice, France|Local Institution, Rennes Cedex, France|Local Institution, Villejuif, France|St. James'S Hospital, Dublin 8, Dublin, Ireland|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Merida, Yucatan, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Oaxaca, Mexico|NKI AVL, Amsterdam, Netherlands|Vu Medical Centre, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Haukeland University Hospital, Bergen, Norway|The Norwegian Radium Hospital, Oslo, Norway|Centrul Medical Sanador, Bucharest, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Marbella, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire, United Kingdom|Royal Marsden Nhs Foundation Trust, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Cardiff, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02823574
35	NCT01642004	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)		Active, not recruiting	Has Results	Squamous Cell Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants|Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint|Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint|Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint|Progression-Free Survival (PFS) at Primary Endpoint|Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint|Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12|Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint|Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	352	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-017|2011-004792-36	September 26, 2012	November 17, 2014	December 29, 2018	July 17, 2012	March 17, 2016	April 10, 2018	Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Ctr, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Cancercare Manitoba, Winnipeg, Manitoba, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Antofagasta, Chile|Local Institution, Santiago, Chile|Local Institution, Praha 8, Czechia|Local Institution, Avignon Cedes 9, France|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, La Roche Sur Yon Cedex 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Bad Berka, Germany|Local Institution, Essen, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Krefeld, Germany|Local Institution, Budapest, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin 9, Dublin, Ireland|Local Institution, Bologna, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Siena, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barakaldo, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Cottingham, EAST Yorkshire, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01642004
36	NCT02041533	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)		Active, not recruiting	Has Results	Stage IV or Recurrent Non-Small Cell Lung Cancer	Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed	Progression-Free Survival in Participants With PD-L1 Expression >= 5%|Progression-Free Survival in All Randomized Participants|Overall Survival in Participants With PD-L1 Expression >= 5%|Overall Survival in All Randomized Participants|Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5%|Duration of Response in Participants With PD-L1 Expression>= 5%|Time to Response in Participants With PD-L1 Expression >= 5%|Disease-related Symptom Improvement Rate by Week 12	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1325	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-026|2012-004502-93	March 25, 2014	July 1, 2016	October 1, 2018	January 22, 2014	July 26, 2017	February 14, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado Hosp, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Cancer Centers of South Texas, San Antonio, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Clinica Colombo, Cordoba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Antwerp University Hospital, Edegem, Belgium|Uz Gent, Gent, Belgium|Uz Leuven, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Olomouc, Czechia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Usti nad Labem, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Vaasa, Finland|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pontoise Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg, France|Sozialstiftung Bamberg, Bamberg, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Wiesbaden, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Matrahaza, Hungary|Azienda Ospedaliera Moscati, Avellino, Italy|Local Institution, Livorno, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Habikino City, Osaka, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Tokyo, Japan|Local Institution, Wakayama, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bydgoszcz, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Wodzislaw Slaski, Poland|Local Institution, Cluj Napoca, Romania|Local Institution, Cluj-napoca, Romania|Local Institution, Ploiesti, Romania|Local Institution, Barcelona, Spain|Local Institution, Las Palmas De Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Chur, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Taipei, Taiwan|Local Institution, Kayseri, Turkey|North Middlesex University Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Trust, Manchester, Greater Manchester, United Kingdom|St James'S University Hospital, Leeds, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02041533
37	NCT03143153	A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin	CheckMate 648	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cisplatin|Drug: Fluorouracil	Overall survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	939	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-648|2016-001514-20	June 19, 2017	May 25, 2020	December 30, 2021	May 8, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, Tucson, Arizona, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Local Institution, Durham, North Carolina, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Local Institution, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Independencia, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Shantou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Instituto Nac. de Cancerologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Local Institution, Odense, Denmark|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Gifu City, Gifu, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Kanazawa, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Niigata-City, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka Sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Takatsuki City, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuga-gun, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinagawa-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Toyama-shi, Toyama, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Japan|Local Institution, Chiba, Japan|Local Institution, Kyoto, Japan|Local Institution, Shizuoka, Japan|Local Institution, Yokohama, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Jeonju-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Ulsan, Korea, Republic of|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Merida, Yucatan, Mexico|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Local Institution, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Focus Lab Plus SRL, Bucuresti, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Keelung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03143153
38	NCT03668119	A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	CheckMate 848	Recruiting	No Results Available	Pan Tumor	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Duration of response (DOR)|ORR|TTR|Clinical benefit rate (CBR)|Overall survival (OS)|PFS|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of laboratory abnormalities|Incidence of anti-drug antibody (ADA)	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	159	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-848|2016-002898-35	October 29, 2018	March 14, 2021	September 8, 2023	September 12, 2018	null	November 20, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Orange, California, United States|Local Institution, Santa Monica, California, United States|Local Institution, Truckee, California, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Niles, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Livingston, New Jersey, United States|Local Institution, Johnson City, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Germantown, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Madison, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Surquillo, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03668119
39	NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)		Active, not recruiting	No Results Available	Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab|Drug: Erlotinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of drug related adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of serious adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of clinical laboratory test by worst toxicity grade|ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of subjects treated in arms A, B, C and D|PFSR based on RECIST 1.1 of subjects treated in arms A, B, C and D|ORR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|PFSR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|ORR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N|PFSR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	472	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-012	December 9, 2011	July 20, 2016	December 29, 2018	October 18, 2011	null	November 7, 2017	Ucla, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01454102
40	NCT03342352	Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)		Withdrawn	No Results Available	Head and Neck Cancer	Drug: Nivolumab|Drug: Epacadostat|Drug: Placebo|Drug: Carboplatin|Drug: Cisplatin|Drug: Cetuximab|Drug: 5-Fluorouracil	Progression-free survival (PFS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Overall survival (OS) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)|Objective response rate (ORR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|Duration of response (DOR) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) and the EXTREME regimen (Arm B)|ORR with nivolumab plus placebo in combination with chemotherapy (Arm C)|PFS with nivolumab plus placebo in combination with chemotherapy (Arm C)|DOR with nivolumab plus placebo in combination with chemotherapy (Arm C)|Time to meaningful symptomatic deterioration (TTSD) with nivolumab plus epacadostat in combination with chemotherapy (Arm A) compared to the EXTREME regimen (Arm B)	Incyte Corporation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA2099NA/ECHO-310	December 15, 2017	April 20, 2018	April 20, 2018	November 14, 2017	null	May 23, 2018			https://ClinicalTrials.gov/show/NCT03342352
41	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 651	Recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cetuximab/Erbitux|Drug: Cisplatin/Platinol|Drug: Carboplatin/Paraplatin|Drug: Fluorouracil/Adrucil	Overall Survival (OS) in participants with PD-L1 expressing tumors|Progression Free Survival (PFS) in pariticipants with PD-L1 expressing tumors|OS in all participants|PFS in all pariticipants|Objective Response Rate (ORR) in all participants|Duration of Response (DOR) in all participants	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	930	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-651|2016-000725-39	August 4, 2016	August 14, 2020	August 15, 2025	April 18, 2016	null	July 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Local Institution, San Francisco, California, United States|Board of Trustees of the Leland Stanford Junior University, Stanford, California, United States|21st Century Oncology Of Jacksonville, Llc, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Univ Of Chicago, Chicago, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Medical Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Fairfax, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|St Vincent'S Hospital (Nsw), Darlinghurst, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Douglas, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Center, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Medical University Of Vienna, Wien, Austria|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Amiens, France|Local Institution, Bordeaux, France|Local Institution, La Tronche, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Villejuif Cedex, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der Albrecht-Ludwigs-Universitat, Freiburg, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Der Universitaet, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin Der Johannes Gutenberg-Universitaet, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Universitat Wurzburg, Wuerzburg, Germany|Local Institution, Athens, Greece|Local Institution, Nea Kifissia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, FC, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, MI, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, TO, Italy|Local Institution, Mestre, VE, Italy|A.O. Santa Croce E Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Perugia, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuke-shi, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Joaquin Gabriel Reinoso Toledo, Monterrey, Nuevo LEON, Mexico|Local Institution, Oaxaca, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Klinika Onkologii i Radioterapii, Gdansk, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Osrodek Badan Klinicznych, Krakow, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, L?Hospitalet De Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Newcastle Upon Tyne, Durham, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT02741570
42	NCT03383458	A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation	CheckMate 9DX	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Biological: Nivolumab|Other: Placebo	Recurrence-free Survival (RFS)|Overall Survival (OS)|Time to recurrence (TTR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	530	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-9DX	December 18, 2017	April 17, 2022	June 7, 2025	December 26, 2017	null	November 20, 2018	Pinnacle Research Group, Llc, Anniston, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA School Of Medicine, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Winship Cancer Institute-Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Laura and Issac Perlmutter Cancer Center at NYU Langone - Belleview Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Impact Migration, Belgium|Local Institution, Leuven, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Bondy, France|Local Institution, Brest, France|Local Institution, Clermont-Ferrand, France|Local Institution, Clichy, France|Local Institution, Creteil Cedex, France|Local Institution, GRENOBLE Cedex 09, France|Local Institution, Lyon Cedex 4, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nice cedex 3, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Reims Cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Etienne, France|Local Institution, Vandoeuvre-les-Nancy, France|Local Institution, Messina, ME, Italy|Local Institution, Cagliari, Italy|Local Institution, Firenze, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Rome, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Gyeongsangnam-do, Korea, Republic of|Local Institution, Jeonnam, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Timisoara, Romania|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Cordoba, Spain|Local Institution, Donostia-San Sebastian, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Sabadell, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Yunlin, Taiwan|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT03383458
43	NCT02864251	A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy	CheckMate722	Recruiting	No Results Available	Non-Small-Cell Lung Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Progression free survival (PFS) in subjects with epidermal growth factor receptor (EGFR) mutation, T790M negative non-small cell lung carcinoma (NSCLC)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS) rate	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	465	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-722	October 20, 2016	September 30, 2019	December 31, 2023	August 11, 2016	null	September 25, 2018	Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Cancer Hematology Oncology, Los Angeles, California, United States|St Joseph Hospital, Orange, California, United States|Torrance Memorial Physican Network, Redondo Beach, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|Baylor Scott and White Research Institute, Temple, Texas, United States|Tyler Hematology/Oncology PA, Tyler, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi`an, Shan1xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Iizuka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Fukuyama, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Himeji, Hyogo, Japan|Local Institution, Itami, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kiriyama-shi, Niigata, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Kishiwada shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Chiba, Japan|Local Institution, Fukuoka, Japan|Local Institution, Niigata, Japan|Local Institution, Tokyo, Japan|Local Institution, Toyama, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheogju-si, Korea, Republic of|Local Institution, Goyang, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Inchoen, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, L'Hospitalet de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung city, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02864251
44	NCT02982954	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer	CHECKMATE 920	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade immune-mediated adverse events (IMAEs)|Time to onset of all high grade IMAEs|Time to resolution of all high grade IMAEs|Percentage of patients who received immune modulating medication due to high grade IMAEs|Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-920	December 7, 2016	March 30, 2020	February 28, 2023	December 6, 2016	null	July 18, 2018	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|eCare, Encinitas, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Kaiser Permanente Medical Group - Southern California, Riverside, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University Of Miami/Sylvester Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Southdale Cancer Clinic, Minneapolis, Minnesota, United States|Park Nicollet Clinic Cancer Center, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Va Medical Center Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Research Center, Fairfax, Virginia, United States|Bon Secours St Francis Hospital, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02982954
45	NCT03438318	Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer		Recruiting	No Results Available	Non Small Cell Lung Cancer	Drug: CMP-001|Drug: Atezolizumab|Radiation: Radiation Therapy	Part A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part A and B: DLT|Part A and B: Oral Temperature|Part A and B: Respiratory Rate|Part A and B: Systolic and Diastolic Blood Pressure|Part A and B: Body Weight|Part A and B: Body Mass Index (BMI)|Part A and B: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters|Part A and B: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters|Part A and B: Concentration of Chemokine IP-10|Part A and B: Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per RECIST V1.1 or iRECIST Using CT/PET or MRI Scans|Part A and B: Time to Response (TTR) as per RECIST V1.1 or iRECIST Using CT/PET or MRI Scans|Part A and B: Duration of Response (DOR) as per RECIST V1.1 or iRECIST Using CT/PET or MRI Scans	Checkmate Pharmaceuticals|Novella Clinical	All	18 Years and older   (Adult, Older Adult)	Phase 1	70	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CMP-001-003	March 15, 2018	December 31, 2019	December 31, 2020	February 19, 2018	null	November 5, 2018	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope Medical Center, Duarte, California, United States|University of Colorado Aurora, Aurora, Colorado, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|MD Anderson, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03438318
46	NCT03527251	Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC	SEQUENCE	Recruiting	No Results Available	Non Small Cell Lung Cancer	Drug: Ipilimumab|Drug: SHR-1210	Safety in the treatment of ipilimumab followed by SHR1210|Overall Response Rate (ORR)|Clinical Benefit Response (CBR)|Progression-free Survival (PFS)|Overall survival (OS)|Duration of response (DOR)|Time To Progression (TTP)	Sun Yat-sen University	All	18 Years and older   (Adult, Older Adult)	Phase 1	10	Other	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-FXY-032	May 15, 2018	December 31, 2018	December 31, 2019	May 17, 2018	null	May 30, 2018	Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT03527251
47	NCT01658878	An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer	CheckMate040	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib	Safety of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Objective response rate (ORR) for Expansion phase of nivolumab|ORR for Nivolumab vs Sorafenib Cohort|Safety of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab Combination Cohort|ORR for Child-Pugh B Cohort|Safety of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort|Complete response (CR) Rate|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|TTP Rate|Progression free survival (PFS)|Overall survival (OS)|Overall survival rate (OSR)|PD-L1 expression|Maximum observed serum concentration (Cmax) of nivolumab|Time of maximum observed serum concentration (Tmax) of nivolumab|Area under the serum concentration time curve in the dosing interval AUC(TAU) of nivolumab|Serum concentration achieved at the end of dosing interval (trough concentration) (Ctrough) of nivolumab|Serum concentration achieved at the end of the infusion (Ceoinf) of nivolumab|Cmax at Cycle 3/ Cmax at Cycle 1 (AI_Cmax) of nivolumab|AUC(TAU) at Cycle 3/ AUC(TAU) at Cycle 1 (AI_AUC) of nivolumab|Effective T-Half of nivolumab	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	620	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-040|2012-001514-42	September 26, 2012	March 31, 2019	December 26, 2019	August 7, 2012	null	November 6, 2018	USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Univ Of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Providence Portland Medical Center, Portland, Oregon, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Local Institution, Angers, France|Local Institution, Creteil Cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 13, France|Local Institution, Reims Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Universitaetsklinikum Essen, Essen, Germany|Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Hong Kong, Hong Kong|Azienda Ospedaliera Di Bologna S. Orsola-Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01658878
48	NCT03669523	Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)	DENIVOS	Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung|Bone Metastases	Drug: Denosumab-nivolumab combination	Overall Response Rate (ORR) according to the PD-L1-expression rate (threshold set at 1%)|Disease-control rate (DCR)|Overall survival|Progression-free survival|Overall Response Rate for the entire population|Overall Response Rate according to the histological type (adenocarcinoma versus squamous cell)|Time to the first Skeletal-Related Event in months|Incidence of adverse events, serious adverse events, deaths and biological abnormalities	Centre Hospitalier de la Région d'Annecy|French Lung Cancer Group	All	18 Years and older   (Adult, Older Adult)	Phase 2	86	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P_2017_007|2018-001105-85	November 6, 2018	September 2022	December 2023	September 13, 2018	null	November 15, 2018	CH du Pays d'Aix, Aix-en-Provence, France|Chu Angers, Angers, France|Centre Hospitalier de La Cote Basque, Bayonne, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Fleyriat, Bourg-en-Bresse, France|CHU Morvan - Institut de Cancérologie et d'Hématologie, Brest, France|Centre François Baclesse, Caen, France|CH Intercommunal, Créteil, France|CH Intercommunal des Alpes du Sud, Gap, France|Hôpital Robert Boulin, Libourne, France|Chu Dupuytren, Limoges, France|CH régional, Longjumeau, France|CH F.Quesnay, Mantes-la-Jolie, France|Hopital Européen, Marseille, France|Hopital Nord APHM, Marseille, France|CH Meaux, Meaux, France|Centre Catalan d'Oncologie, Perpignan, France|CH Annecy-Genevois, Pringy, France|CHU Hôpital Pontchailloux, Rennes, France|CHU La Réunion - Site de Bellepierre, Saint-Denis, France|Groupe Hospitalier Sud Réunion - CHU de la Réunion, Saint-Pierre, France|Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France|CLCC Paul Strauss, Strasbourg, France|Centre Hospitalier de Bigorre, Tarbes, France|Hôpital d'Instruction des Armées Saint-Anne, Toulon, France|CHITS Toulon Sainte-Musse, Toulon, France|Hôpital André Mignot Centre Hospitalier de Versailles, Versailles, France|CH Villefranche sur Saone, Villefranche-sur-Saône, France		https://ClinicalTrials.gov/show/NCT03669523
49	NCT02186249	Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma	CheckMate218	No longer available	No Results Available	Malignant Melanoma	Drug: Nivolumab|Drug: Ipilimumab		Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)		null	Industry	Expanded Access		CA209-218	null	null	null	July 10, 2014	null	February 8, 2017	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|6501 Truxtun Avenue, Bakersfield, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|100 UCLA Medical Plaza, Los Angeles, California, United States|514 North Prospect Ave, Redondo Beach, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Angeles Clinic and Research Institute, Santa Monica, California, United States|1325 East Church Street, Santa Monica, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Smilow Cancer Hospital at Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Memorial Regional Hospital, Hollywood, Florida, United States|4500 San Pablo Road South, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|UF Health Cancer Center at Orlando Health, Longwood, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|600 Celebrate Life Parkway, Newnan, Georgia, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, United States|Oncology Specialists, SC, Niles, Illinois, United States|Local Institution, Louisville, Kentucky, United States|Medstar Health Research Institute, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Atlantic Health System, Morristown, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Tulsa Cancer Institute PLLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists PC, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St Luke's Hospital, Bethlehem, Pennsylvania, United States|Greenville Health System, Easley, South Carolina, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology, Midland, Texas, United States|Texas Oncology, Paris, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc, Roanoke, Virginia, United States|Shenandoah Oncology Association, Winchester, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Grand River Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Chuq Centre Hospitalier Universitaire de Quebec, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02186249
50	NCT02726581	An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma	CheckMate 602	Active, not recruiting	No Results Available	Multiple Myeloma	Biological: Nivolumab|Biological: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone	Progression free survival (PFS) by Independent Review Committee (IRC)|Time to objective response (TTR)|Duration of objective response (DOR)|Investigator-assessed PFS|Investigator-assessed ORR|Objective response rate (ORR) by IRC|Overall Survival (OS)	Bristol-Myers Squibb|AbbVie	All	18 Years and older   (Adult, Older Adult)	Phase 3	348	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-602|2015-005699-21	April 21, 2016	March 15, 2020	December 8, 2022	April 1, 2016	null	November 6, 2018	Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Compassionate Cancer Res Grp, Fountain Valley, California, United States|Scripps Health Dba Scripps Clinical Research Services, La Jolla, California, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ronald Reagan Ucla Medical Center, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Compassionate Cancer Res Grp, Riverside, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|St. Mary's Hospital Med Ctr, Grand Junction, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Ctr, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Department Of Medicine Division Of Hematology/Oncology, Worcester, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Local Institution, Flemington, New Jersey, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Local Institution, New Brunswick, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|University Of Oklahoma, Oklahoma City, Oklahoma, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Scott And White Memorial Hosp, Temple, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Elisabethinen Hospital Dept of Medicine, Linz, Austria|Universitaetsklinik Salzburg, Salzburg, Austria|Akh, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Wilhelminenspital, Wien, Austria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|CIUSSS du Nord-de-l'ile-de-Montreal - Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Quebec, Canada|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika hematoonkologie, Ostrava-Poruba, Czechia|I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Odense, Denmark|Charite Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Uniklinikum Duesseldorf, Duesseldorf, Germany|Universitaetsklink Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Alexandra General Hospital Of Athens, Athens, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, Stockholm, Sweden|Hopitaux Universitaires de Geneve, Geneve, Switzerland		https://ClinicalTrials.gov/show/NCT02726581
51	NCT03683407	Effect of Chemotherapy on TMB in NSCLC		Recruiting	No Results Available	Chemotherapy Effect|Immunotherapy|Tumor Mutation Burden|PD-1/L1 Inhibitor	Other: Next-Genernation Sequence	Tumor Mutation Burden Change	Baodong Qin|Shanghai Changzheng Hospital	All	18 Years to 75 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COTMB	September 1, 2018	February 28, 2019	August 31, 2019	September 25, 2018	null	September 25, 2018	Shanghai Changzheng Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03683407
52	NCT02105636	Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)		Active, not recruiting	Has Results	Squamous Cell Carcinoma of the Head and Neck	Drug: Nivolumab|Drug: Cetuximab|Drug: Methotrexate|Drug: Docetaxel	Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint|Overall Survival (OS) Rate in All Randomized Participants at Primary Endpoint|Progression-Free Survival (PFS)|Objective Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	506	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-141|2013-003622-86	May 1, 2014	November 6, 2015	October 27, 2020	April 7, 2014	January 11, 2017	August 2, 2018	Stanford University Medical Center, Stanford, California, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Crescent City Research Consortium, LLC, Metairie, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Dumc, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Cancer Clinic, Nashville, Tennessee, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|COIBA, Berazategui, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Med Hochschule Hannover, Hannover, Germany|Klinikum Der Universitaet, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola, FC, Italy|Local Institution, Milano, MI, Italy|Local Institution, Torino, TO, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02105636
53	NCT03138161	SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma		Recruiting	No Results Available	Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma	Drug: Trabectedin|Drug: Ipilimumab|Drug: Nivolumab	Maximum tolerated dose|Objective response rate (ORR), disease control rate (DCR)|Progression free survival (PFS), 6 month PFS rate|Overall survival (OS), 6 month OS rate	Sarcoma Oncology Research Center, LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SOC-1702	April 13, 2017	June 30, 2020	August 31, 2020	May 3, 2017	null	September 6, 2018	Sarcoma Oncology Research Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT03138161
54	NCT03507699	Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer		Not yet recruiting	No Results Available	Colorectal Neoplasms Malignant|Liver Metastases	Radiation: Liver radiation therapy|Drug: Nivolumab Injection [Opdivo]|Drug: Ipilimumab Injection [Yervoy]|Drug: CMP-001	Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0|Response rate as assessed by RECIST v1.1|Progression free survival	Sheba Medical Center|Checkmate Pharmaceuticals|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	19	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4465-17-SMC|CA209-991	July 1, 2018	May 31, 2020	May 31, 2021	April 25, 2018	null	April 25, 2018	Sheba Medical Center, Ramat Gan, Israel		https://ClinicalTrials.gov/show/NCT03507699
55	NCT03701607	Effect of Chemotherapy on PD-L1 in NSCLC		Recruiting	No Results Available	Chemotherapy|Immunotherapy|PD-L1	Other: PD-L1 group	Number of participants with PD-L1 positive as assessed by immunohistochemical assay	Baodong Qin|Shanghai Changzheng Hospital	All	18 Years to 75 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	COPDL1	September 1, 2018	February 28, 2019	August 31, 2019	October 10, 2018	null	October 10, 2018	Shanghai Changzheng Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03701607
56	NCT03618641	CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease		Recruiting	No Results Available	Melanoma|Lymph Node Cancer	Drug: CMP-001|Biological: Nivolumab	Pathologic Response Rate (PRR)|Relapse-Free Survival (RFS)|Overall Survival (OS)	Diwakar Davar|Checkmate Pharmaceuticals|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-169	August 8, 2018	July 1, 2020	July 15, 2023	August 7, 2018	null	October 12, 2018	UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03618641
57	NCT02899299	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	CheckMate743	Active, not recruiting	No Results Available	Mesothelioma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-743|2016-001859-43	October 25, 2016	October 4, 2020	September 28, 2021	September 14, 2016	null	November 20, 2018	Ucsf, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Univ Of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Allegheny Cancer Center, Jefferson Hills, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Coswig, Germany|Local Institution, Essen, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg an d. Saar, Germany|Local Institution, Immenhausen, Germany|Local Institution, Koeln, Germany|Local Institution, Moers, Germany|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Istituto Tumori Giovanni Paolo II, Bari, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Ospedale Policlinico San Martino, Genova, Italy|Aorn Dei Colli, Napoli, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuyama-shi, Hiroshima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Amagasaki-shi, Hyogo, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Medica Sur, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bytom, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Bern, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Diyarbak?r, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Seyhan, Turkey|Local Institution, Truro, Cornwall, United Kingdom|Edinburgh Cancer Centre, Edinburgh, Midlothian, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02899299
58	NCT02596035	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma	CheckMate 374	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab	Incidence of high grade (Grade 3-4 and Grade 5) IMAEs in subjects with advanced or metastatic renal cell carcinoma (RCC) who are treated with nivolumab monotherapy|Median time to onset of high grade (Grade 3-4) IMAEs|Median time to resolution of high grade (Grade 3-4) IMAEs|Percentage of subjects who receive immune modulating medication for the immune-mediated event|Percentage of subjects who receive hormonal replacement therapy for the immune-mediated event|Percentage of subjects who receive ≥ 40 mg prednisone equivalents for the immune-mediated event|Total duration of all immune modulating medications given for the immune-mediated event	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	197	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CA209-374|2015-003286-28	November 30, 2015	May 1, 2018	December 1, 2021	November 4, 2015	null	November 1, 2018	Arizona Oncology Associates, Phoenix, Arizona, United States|St. Jude Hospital Yorba Linda, Fullerton, California, United States|Cancer Care Associates Medical Group, Inc., Los Angeles, California, United States|Comprehensive Blood And Cancer Center, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado, Aurora, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Center For Cancer And Blood Disorders, Bethesda, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Urology Cancer Center Laboratory, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology, Johnson City, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists - East DBA Compass Oncology - East, Portland, Oregon, United States|Local Institution, Springfield, Oregon, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Blue Ridge Cancer Care, DFW Airport, Texas, United States|Cancer Centers of South Texas, DFW Airport, Texas, United States|Nebraska Methodist Hospital, DFW Airport, Texas, United States|Sansum Santa Barbara Medical Foundation Clinic, DFW Airport, Texas, United States|Texas Cancer Center - Sherman, DFW Airport, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, Houston, Texas, United States|Texas Oncology, Paris, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|Local Institution, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT02596035
59	NCT02599402	Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma	CheckMate 401	Active, not recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: Ipilimumab	Rate and frequency for high-grade (CTCAE v4.0 Grade 3-5) treatment-related, select adverse events in study subjects|Incidence of all high-grade (Grades 3-5), select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Resolution of an Adverse Event (AE)|Overall survival time from first dosing date to the date of death.|Safety will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|Tolerability will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|ORR|Investigator-assessed Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	615	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-401|2015-001274-17	December 8, 2015	December 19, 2021	December 20, 2021	November 6, 2015	null	August 1, 2018	Local Institution, Garran, Australian Capital Territory, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Tiwi, Northern Territory, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Nedlands, Australia|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, Boulogne Billancourt, France|Local Institution, Cedex, France|Local Institution, Clermont-Ferrand, France|Local Institution, Dijon, France|Local Institution, Le Mans, France|Local Institution, Lille, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Rouen, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg im Breisgau, Germany|Local Institution, Gottingen, Germany|Local Institution, Hannover, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Luebeck, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Stade, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Eskilstuna, Sweden|Local Institution, Gavle, Sweden|Local Institution, Karlskrona, Sweden|Local Institution, Karlstad, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Solna, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Basel, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Sheffield, Yorkshire, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT02599402
60	NCT02142218	Expanded Access Program With Nivolumab to Treat Melanoma	Checkmate 168	No longer available	No Results Available	Stage III (Unresectable) or Stage IV Advanced Melanoma	Drug: Nivolumab		Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)		null	Industry	Expanded Access		CA209-168	June 2014	May 2018	May 2018	May 20, 2014	null	September 29, 2016	Local Institution, Mobile, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Local Institution, Encinitas, California, United States|Local Institution, Washington, District of Columbia, United States|Lynn Cancer Institute At Boca Raton Regional Hospital, Boca Raton, Florida, United States|Cancer Specialists Of North Florida, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Florida Hospital, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Oncology Hematology Associates Of Sw In, Newburgh, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Mid Ohio Oncology/Hematology, Inc,Dba, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke'S Hospital, Bethlehem, Pennsylvania, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Jd. Petropolis-Londrina, Parana, Brazil|Local Institution, Ijui, Rio Grande do Sul, Brazil|Local Institution, Passo Fundo, Rio Grande do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Ribeirao Preto, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, North Vancouver, British Columbia, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Quebec, Canada|Local Institution, Bogota, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Local Institution, Medellin, Colombia|Local Institution, Medellin, Colombia|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru		https://ClinicalTrials.gov/show/NCT02142218
61	NCT02388906	Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab	Recurrence -free-survival|Overall survival	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	15 Years and older   (Child, Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-238|2014-002351-26	March 12, 2015	November 29, 2018	November 26, 2019	March 17, 2015	null	July 3, 2018	University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Nyu Clinical Cancer Institute, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System / Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Graz, Austria|Local Institution, Salzburg, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Mcgill University Dept Of Oncology, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Ostrava-Poruba, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Budapest, Hungary|Local Institution, Dublin 7, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital General Univ De Valencia, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02388906
62	NCT03138499	A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,	CheckMate 812	Recruiting	No Results Available	Hodgkin's Disease	Biological: Nivolumab|Biological: Brentuximab vedotin	Progression Free Survival (PFS)|Complete Response Rate (CRR)|Objective Response Rate (ORR)|Duration of response (DOR)|Duration of complete response (DOCR)|Overall Survival (OS)	Bristol-Myers Squibb|Seattle Genetics, Inc.|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	340	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-812|2017-000847-41	May 16, 2017	November 29, 2020	July 27, 2023	May 3, 2017	null	November 20, 2018	Dr. Moh'd Khushman MD, Office of, Mobile, Alabama, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Califomia, Los Angeles, Los Angeles, California, United States|Local Institution, Palo Alto, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut, Plainville, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Parkview Cancer Center, Fort Wayne, Indiana, United States|University of Kansas Hospital, Westwood, Kansas, United States|Louisville Oncology, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Mercy Clinic Oncology and Hematology - Joplin, Joplin, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Memorial Sloan-Kettering Cancer Center (MSKCC) - Basking Ridge, Basking Ridge, New Jersey, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center Monmouth, Middletown, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University Brody School of Medicine(ECU), Greenville, North Carolina, United States|Local Institution, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Greenville Health System Cancer Institute, Spartanburg, South Carolina, United States|Center For Biomedical Research, Knoxville, Tennessee, United States|UT Medical Center Cancer Institute, Knoxville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Vista Oncology - East Olympia, Olympia, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Local Institution, Albury, New South Wales, Australia|Local Institution, Randwick, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prague 2, Czechia|Local Institution, Debrecen, Hungary|Local Institution, Milano, Italy|Local Institution, Reggio Emilia, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, San Juan, Puerto Rico|Local Institution, Ankara, Turkey|Local Institution, Samsun, Turkey		https://ClinicalTrials.gov/show/NCT03138499
63	NCT02581631	An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas	CheckMate 436	Recruiting	No Results Available	Non-Hodgkin's Disease	Biological: Nivolumab|Drug: Brentuximab Vedotin	Safety of combination of nivolumab and brentuximab vedotin based on incidence of deaths, adverse events (AE), serious adverse events (SAE), AE leading to discontinuation, AE leading to dose delay, drug-related adverse events|Tolerability of combination of nivolumab and brentuximab vedotin based on incidence of deaths, AE, SAE, adverse events leading to discontinuation, adverse events leading to dose delay, drug-related adverse events|Overall Response Rate (ORR)|Overall duration of response (DOR)|Complete response rate (CRR)|Duration of complete response|Progression-Free Survival (PFS)|Overall Survival (OS)	Bristol-Myers Squibb|Seattle Genetics, Inc.	All	15 Years and older   (Child, Adult, Older Adult)	Phase 1|Phase 2	146	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-436|2015-003286-28	December 18, 2015	June 9, 2019	February 13, 2020	October 21, 2015	null	September 25, 2018	University of Alabama At Birmingham, Birmingham, Alabama, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Hackensack, New Jersey, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Rochester, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Rozzano (milano), Italy|Hospital Duran I Reynals, Hospitalet de Llobregat - Barcelona, Spain|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02581631
64	NCT02927769	A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment	CheckMate 744	Recruiting	No Results Available	Hodgkin Disease	Biological: Nivolumab|Biological: brentuximab vedotin|Biological: bendamustine	Event Free Survival (EFS)|Complete Metabolic Response (CMR) rate prior to HDCT/ASCT|Complete Metabolic Response (CMR) rate at any time prior to radiation therapy|Overall Response Rate (ORR) after 4 cycles of nivolumab + brentuximab vedotin treatment|Progression Free Survival Rate (PFSR)|Duration of Response (DOR)|Incidence of serious and non-serious adverse events of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant abnormalities in general laboratory tests of nivolumab (BMS-936558) and brentuximab when given in combination.|Incidence of clinically significant vital sign measurements of nivolumab (BMS-936558) and brentuximab when given in combination.	Bristol-Myers Squibb|Seattle Genetics, Inc.	All	5 Years to 30 Years   (Child, Adult)	Phase 2	80	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-744|2016-002347-41	March 27, 2017	March 28, 2021	March 27, 2022	October 7, 2016	null	November 20, 2018	Children'S Hospital Of Alabama, Birmingham, Alabama, United States|Phoenix Children'S Hospital, Phoenix, Arizona, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Local Institution, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children'S Hospital & Research Center At Oakland, Oakland, California, United States|Local Institution, Orange, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, San Francisco, California, United States|Childrens Hospital of Colorado, Aurora, Colorado, United States|Local Institution, Hartford, Connecticut, United States|Smilow Cancer Hospital At Yale New Haven Hospital, New Haven, Connecticut, United States|Nemours / A. I. duPont Hospital for Children, Wilmington, Delaware, United States|Children'S National Medical Center, Washington, District of Columbia, United States|Nemours Children'S Clinic, Jacksonville, Florida, United States|All Children'S Hospital, Saint Petersburg, Florida, United States|Children's Healthcare Of Atlanta, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Indiana University - Riley Children'S Hospital, Indianapolis, Indiana, United States|University Of Iowa, Iowa City, Iowa, United States|Local Institution, Louisville, Kentucky, United States|John Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution, Detroit, Michigan, United States|Local Institution, Grand Rapids, Michigan, United States|Local Institution, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Children'S Mercy Hospital And Clinics, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Local Institution, New Hyde Park, New York, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Valhalla, New York, United States|UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children'S Hospital, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States|Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Dell Children'S Medical Center Of Central Texas, Austin, Texas, United States|The University Of Texas, Dallas, Texas, United States|Local Institution, Fort Worth, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Local Institution, Fairfax, Virginia, United States|Children'S Hosp-Kings Daughter, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Childrens Hospital, Seattle, Washington, United States|Children'S Hospital Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Klinika detske hematologie a onkologie, Praha 5, Czechia|Local Institution, Lille cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 12, France|Hopital Robert Debre, Paris, France|Local Institution, Toulouse cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif Cedex, France|Campus Virchow Klinikum Der Charite, Berlin, Germany|Uniklinikum Giessen und Marburg, Giessen, Germany|Mhh Kinderklinik, Hannover, Germany|Dr. von Haunersches Kinderspital, Muenchen, Germany|Local Institution, Dublin, Ireland|Cro-Aviano, Aviano (PN), Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Irccs Istituto G. Gaslini, Genova, Italy|Fondazione Monza e Brianza per il Bambino e la sua Mamma MBBM, Monza (mb), Italy|Ao Santobono - Pausilipon, Napoli, Italy|AOU Policlinico Umberto I, Roma, Italy|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Leeds, North Yorkshire, United Kingdom|Local Institution, Leeds, WEST Yorkshire, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Nottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT02927769
65	NCT02857426	A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)	CheckMate 647	Recruiting	No Results Available	Lymphoma	Drug: Nivolumab	Objective response rate (ORR)|Progression-free survival (PFS)|Duration of response (DOR)|Overall survival (OS)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 2	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-647|2016-000894-19	October 18, 2016	June 9, 2019	December 6, 2019	August 5, 2016	null	October 23, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|City Of Hope Medical Center, Duarte, California, United States|UCSF Medical Center, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University Of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Nancy, France|Local Institution, Paris cedex 13, France|Centre Hospitalier Lyon Sud - UPCO, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, St. Cloud, France|Local Institution, Tours Cedex 9, France|Local Institution, Heidelberg, Germany|Klinikum Stuttgart, Stuttgart, Germany|Local Institution, Hong Kong, Hong Kong|I. sz. Belgyogyaszati Klinika SE, Budapest, Hungary|Belgyogyaszati Onkologia OOI, Budapest, Hungary|II. sz. Belgyogyaszati Klinika DEKK, Debrecen, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Tel Aviv, Israel|Irccs Ospedale S. Raffaele, Milano, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Kotoku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata, Japan|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Bellinzona, Switzerland		https://ClinicalTrials.gov/show/NCT02857426
66	NCT03138512	A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma	CheckMate 914	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Placebo	Disease-free survival (DFS)|Overall Survival (OS)|Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-914|2016-004502-34	July 5, 2017	September 5, 2022	July 7, 2023	May 3, 2017	null	November 20, 2018	Alabama Oncology, Birmingham, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Local Institution, New Haven, Connecticut, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Local Institution, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Local Institution, Evansville, Indiana, United States|Washington University, Saint Louis, Missouri, United States|Meridan Health System-Jersey Shore Medical Center, Neptune, New Jersey, United States|Local Institution, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Providence Newburg Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica CER San Juan, San Juan, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Randwick, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|ICON Cancer Center, Chermside, Queensland, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Liege, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Xi?an, China|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Besancon, France|Local Institution, La Roche sur Yon, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Tours Cedex, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Essen, Essen, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Grosshadern, Munich, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Universitaetsklinikum Rostock, Rostock, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Arezzo, Italy|A.O. Istituti Ospitalieri Di Cremona, Cremona, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Di Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Policlinico G. Rossi, Verona, Italy|Local Institution, Toyoake Shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Lublin, Poland|Local Institution, Warsaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital San Pedro De Alcantara, Caceres, Spain|H. Lucus Augusti, Lugo, Spain|Local Institution, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Sevilla, Spain|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT03138512
67	NCT03029780	An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma	CheckMate 800	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Biological: Opdivo|Biological: Yervoy	Incidence of adverse events (AEs) in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of AEs in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of grade 3-5 AEs|Nivolumab as measured using serum concentration- time data|Ipilimumab as measured using serum concentration- time data|Anti-nivolumab antibody|Anti-ipilimumab antibody|Maximum observed serum concentration (Cmax)|Objective Response Rate (ORR)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-800	February 9, 2017	November 27, 2017	February 21, 2021	January 24, 2017	null	April 30, 2018	Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile		https://ClinicalTrials.gov/show/NCT03029780
68	NCT03068455	An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma	CheckMate 915	Active, not recruiting	No Results Available	Melanoma	Biological: nivolumab|Biological: ipilimumab	Recurrence-free survival (RFS)|Overall Survival (OS)|PD-L1 expression	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	2000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-915|2016-003729-41	April 7, 2017	November 8, 2020	February 17, 2023	March 1, 2017	null	October 9, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University Of Chicago, Chicago, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Med Ctr, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Centre Hospitalier Universitaire Dijon Bocage, Dijon, France|Hopital Claude Huriez, LILLE Cedex, France|Hopital De La Timone, Marseille Cedex 5, France|Chu Nantes, Nantes, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Luebeck, Germany|Local Institution, Muenchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Metropolitan Hospital, Athens, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Ospedale Policlinico San Martino, Genova, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Tauranga, BAY OF Plenty, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Dunedin, New Zealand|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Hospital Regional Universitario De Malaga, Malaga, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital Universitario Y Politecnico La Fe, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|The Beatson West Of Scotland Cancer Centre, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital Nhs Trust, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton., United Kingdom		https://ClinicalTrials.gov/show/NCT03068455
69	NCT02320058	An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself	CheckMate204	Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab	Intracranial Clinical Benefit Rate (CBR)|Extracranial Clinical Benefit Rate|Overall Survival (OS)|Number of adverse events (AEs)|Number of serious adverse events (SAEs)|Number AEs leading to death|Number of clinically significant abnormalities in general laboratory tests in combination with Ipilimumab and Nivolumab|Objective response rate (ORR)|Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	119	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-204	January 5, 2015	November 3, 2022	November 4, 2022	December 19, 2014	null	May 22, 2018	City of Hope, Duarte, California, United States|Angeles Clinic and Research Institute, Los Angeles, California, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|The California Pacific Medical Research Institute, San Francisco, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Aventura, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Loyola University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Weinberg Cancer Institute At Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case School of Medicineuniversity Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St Luke's Health Network, Easton, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT02320058
70	NCT01927419	Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma	CheckMate 069	Active, not recruiting	Has Results	Unresectable Melanoma|Metastatic Melanoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo	Percentage of Participants With Investigator-assessed Objective Response in the Randomized, BRAF Wild-type Population|Percentage of Participants With Investigator-assessed Objective Response in the Randomized Population|Investigator-assessed Progression-free Survival (PFS) in All Populations|Percentage of BRAF Mutation-positive Participants With Investigator-assessed Objective Response|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Overall Quality of Life (QOL) Score	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	179	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-069|2013-002018-11	August 21, 2013	July 24, 2014	February 6, 2019	August 22, 2013	February 8, 2016	April 9, 2018	San Francisco Oncology Associates, San Francisco, California, United States|Orlando Health Inc, Orlando, Florida, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Easton, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison, Wisconsin, United States|Local Institution, Toulouse, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT01927419
71	NCT01721772	Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma	CheckMate 066	Active, not recruiting	Has Results	Melanoma	Biological: BMS-936558 (Nivolumab)|Biological: Placebo matching BMS-936558 (Nivolumab)|Drug: Dacarbazine|Drug: Placebo matching Dacarbazine	Overall Survival (OS)|Overall Survival (OS) Rate|Progression-free Survival (PFS)|Progression-free Survival (PFS) Rate|Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival by Programmed Cell Death Ligand 1 (PD-L1) Expression Level|Change From Baseline in Health-related Quality of Life (HRQoL) Scores	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	583	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-066|2012‐003718‐16	January 17, 2013	June 24, 2014	February 23, 2019	November 6, 2012	February 25, 2016	August 8, 2018	Fundacion Cidea, Capital Federal, Buenos Aires, Argentina|Instituto Medico Especialazado Alexander Fleming, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, North Sydney, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Qe Ii Health Science Centre, Halfax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Mcgill University, Dept. Oncology, City, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Koeln, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Nuernberg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Tubingen, Germany|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Local Institution, Mexico City, Mexico|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, San Sebastian, Guipuzcoa, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Umea, Sweden		https://ClinicalTrials.gov/show/NCT01721772
72	NCT03141177	A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma	CheckMate 9ER	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Drug: Cabozantinib|Drug: Sunitinib|Biological: Ipilimumab	Progression Free Survival (PFS) per blinded independent central review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR)|Incidence of adverse events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb|Exelixis|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	630	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9ER|2017-000759-20	July 11, 2017	September 22, 2019	April 22, 2023	May 4, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Daphne, Alabama, United States|Cancer Treatment Centers of America-Western, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Southeastern Regional Medical Center - CTCA, Newnan, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Midland, Texas, United States|Local Institution, Plano, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Seattle, Washington, United States|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel De Tucuman, Tucuman, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Affinity Clinical Research Services Pty Ltd, Doubleview, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Klinik Essen-Mitte, Essen, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Rechts Der Isar Der Tum, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Alexandra General Hospital, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy|Local Institution, Pavia, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Arakawa-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Fukuoka, Japan|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clincia, Merida, Yucatan, Mexico|Local Institution, Monterrey, NL, Mexico|Hospital Medica Tec 100, Queretaro, Mexico|WSS w Bialej Podlaskiej, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Depar, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Denizli, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT03141177
73	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients	CheckMate 143	Active, not recruiting	No Results Available	Recurrent Glioblastoma	Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab	Cohorts 1,1b, 1c and 1d : Safety and tolerability based on drug related events leading to permanent discontinuation prior to completing 4 doses|Cohort 2: Overall Survival (OS)|Cohort 2: Overall Survival rate (OS)|Cohort 2: Progression Free Survival (PFS)|Cohort 2: Objective Response Rate(ORR)	Bristol-Myers Squibb	All	Child, Adult, Older Adult	Phase 3	626	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-143|2013-003738-34	January 27, 2014	January 10, 2017	October 26, 2018	December 23, 2013	null	March 16, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Aarhus University Hospital, Aarhus C, Denmark|Odense University Hospital, Odense C, Denmark|Local Institution, Bron cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT02017717
74	NCT02181738	Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)	CheckMate 205	Active, not recruiting	No Results Available	Hodgkin Disease	Drug: Nivolumab|Drug: Doxorubicin|Drug: Vinblastine|Drug: Dacarbazine	Independent radiologic review committee (IRRC) assessed objective response rate (ORR)|proportion of subjects who experienced at least one treatment-related Grade 3 5 AEs (per NCI CTCAE version 4.0 criteria, any PT term) with an onset date after or on the first dose date and no later than 30 days after the last study dose date|Duration of response (DOR)|Complete remission (CR) rate|CR duration|Partial remission (PR) rate|PR duration|Investigator-assessed ORR|Investigator-assessed DOR|Treatment discontinuation rate, defined by the number of subjects who were treated with fewer than 12 doses|Treatment discontinuation rate of nivolumab monotherapy|Treatment discontinuation rate of the Nivolumab-AVD combination therapy|Treatment discontinuation rate of the combination therapy|Incidence of treatment related grade 3-5 AEs during the monotherapy phase|Incidence of treatment related grade 3-5 AEs during the combination phase	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	338	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-205|2014-001509-42	July 19, 2014	August 31, 2017	October 1, 2020	July 4, 2014	null	January 23, 2018	Cedars Sinai Medical Center, Los Angeles, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Med Coll/Ny Pres, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Universitaetsklinikum Innsbruck, Innsbruck, Austria|Department Fuer Haematologie, Wien, Austria|Local Institution, B-leuven, Belgium|Local Institution, Gent, Belgium|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Praha 2, Czechia|Local Institution, Berlin, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitaetsklinik Koeln, Koeln, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Local Institution, Bologna, Italy|Local Institution, Napoli, Italy|Istituto Clinico Humanitas, Rozzano (milano), Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Utrecht, Netherlands|Hospital Costa Del Sol, Marbella, Malaga, Spain|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Singleton Hospital, Swansea, Carmarthenshire, United Kingdom|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02181738
75	NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)		Active, not recruiting	Has Results	Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Sunitinib	Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Investigator-assessed Objective Response Rate(ORR) in Any Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-214|2014-001750-42	October 13, 2014	June 26, 2017	September 30, 2019	September 4, 2014	October 16, 2018	October 16, 2018	City Of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Kansas Cancer Center, Fairway, Kansas, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Isr. Deacon. Med Cnt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centro De Cancer, Pontificia Universidad Catolica, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina del Mar, Chile|Local Institution, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Instituto de Cancerologia SA, Medellin, Colombia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Liberec, Czechia|Local Institution, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Local Institution, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Aachen, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Jena, Germany|Local Institution, Magdeburg, Germany|Local Institution, Muenchen, Germany|Local Institution, Muenster, Germany|Local Institution, Ulm, Germany|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Pecs, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Ospedal S. Donato Usl 8, Arezzo, Italy|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola (fc), Italy|Local Institution, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital General De Asturias, Oviedo, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska University Hospital, Solna, Sweden|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Swansea, United Kingdom	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02231749
76	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)		Active, not recruiting	Has Results	Advanced or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Percentage of Participants With Treatment-related Grade 3-5 Adverse Events (AEs) During the Induction Periods|Investigator-assessed Response Rate at Week 25|Investigator-assessed Duration of Response (DOR)|Investigator-assessed Rate of Progression	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	177	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-064	April 17, 2013	April 3, 2015	October 18, 2019	February 5, 2013	April 11, 2016	August 2, 2018	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01783938
77	NCT01668784	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)		Active, not recruiting	Has Results	Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma	Biological: Nivolumab|Drug: Everolimus	Overall Survival (OS) at Primary Endpoint|Investigator-assessed Objective Response Rate (ORR) at Primary Endpoint|Investigator-assessed Duration of Objective Response at Primary Endpoint|Investigator-assessed Time to Objective Response at Primary Endpoint|Investigator-assessed Time of Progression-free Survival (PFS) at Primary Endpoint|Overall Survival (OS) by Programmed Death-Ligand 1 (PD-L1) Expression Level at Primary Endpoint|Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events at Primary Endpoint|Percentage of Participants With Disease-related Symptom Progression (DRSP) at Primary Endpoint|Number of Participants Meeting Marked Laboratory Abnormality Criteria in Specific Liver and Thyroid Tests at Primary Endpoint|Number of Participants With Abnormal Hematology and Serum Chemistry Laboratory Parameters by Worse CTC Grade - SI Units	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1068	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-025|2011‐005132‐26	September 27, 2012	May 6, 2015	September 28, 2018	August 20, 2012	April 29, 2016	January 24, 2018	Highland Oncology Group, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Southern California, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|University Of Washington, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Melbourne, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Centre D'Oncologie Dr-Leon-Richard, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halfax, Nova Scotia, Canada|Lakeridge Health Oshawa-Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum, Hopital Notre-Dame, Montreal, Quebec, Canada|Smbd Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Prague 5, Czechia|Local Institution, Aarhus C, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Munich, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Arezzo, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rozzano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Higashi-ku, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama, Kangawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kobe-city, Hyogo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Rybnik, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Iasi, Romania|Local Institution, Timisoara, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Hospitalet De Llobregat, Barcelona, Spain|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Solna, Sweden|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT01668784
78	NCT01844505	Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)		Active, not recruiting	Has Results	Unresectable or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab	Progression Free Survival (PFS)|Overall Survival (OS)|Rate of Overall Survival|Rate of Progression-Free Survival|Objective Response Rate (ORR) Per Investigator Assessment|Progression-Free Survival Based on PD-L1 Expression Level|Overall Survival Based on PD-L1 Expression Level|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Social Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Cognitive Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Emotional Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Role Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1296	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-067|2012-005371-13	May 23, 2013	August 1, 2016	March 31, 2019	May 1, 2013	September 26, 2017	March 16, 2018	Banner-MD Anderson Cancer Center, Gilbert, Arizona, United States|University Of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic And Research Institute., Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|Comprehensive Cancer Center At Desert Regional Medical Ctr, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, Pc, Clifton Park, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Boulogne Billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Pamplona-Navarra, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Geneva, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Zürich, Switzerland|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01844505
79	NCT01472081	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)		Active, not recruiting	No Results Available	Renal Cell Carcinoma|Clear-cell Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Pazopanib|Drug: Sunitinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Adverse event (AE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Serious adverse event (SAE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by Objective Response Rate (ORR)|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1	175	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-016	January 2012	February 2016	June 2018	November 16, 2011	null	April 19, 2017	City Of Hope, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Bc Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Hospital-Uhn, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01472081
80	NCT01721746	A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)		Active, not recruiting	Has Results	Unresectable or Metastatic Melanoma	Biological: BMS-936558|Drug: Dacarbazine|Drug: Carboplatin|Drug: Paclitaxel	Objective Response Rate (ORR)|Median Overall Survival (OS) at Primary Endpoint|Median Months of Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRC/IRRC)|Objective Response Rate (ORR) by Baseline PD-L1 Expression|Median Overall Survival (OS) Time in Months by Baseline PD-L1 Expression|Mean Change From Baseline in Health-related Quality of Life (HRQoL) Global Health Status Scores	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	631	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-037|2012-001828-35	December 13, 2012	February 16, 2016	March 6, 2019	November 6, 2012	March 22, 2017	September 26, 2017	Mayo Clinic, Scottsdale, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Ucsf Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Oncology And Hematology, Portland, Oregon, United States|Network Office of Research and Innovation, Allentown, Pennsylvania, United States|St. Luke'S Health System, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Chum-Hopital Notre-Dame, Montreal, Quebec, Canada|Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada|Aarhus Universitetshospital, Aarhus, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Clermont Ferrand, France|Local Institution, Lille Cedex, France|Local Institution, Marseille, France|Local Institution, Nantes Cedex 1, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Villejuif, France|Local Institution, Wuerzburg, Bayern, Germany|Local Institution, Buxtehude, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Luebeck, Germany|Local Institution, Magdeburg, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Jerusalem, Israel|Local Institution, Ramat Gan, Israel|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom		https://ClinicalTrials.gov/show/NCT01721746
81	NCT02156804	A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)		Active, not recruiting	No Results Available	Melanoma	Drug: Nivolumab (BMS-936558)	Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma|Rate and frequency of AEs regardless of causality|Rate and frequency of treatment-related AEs|Rate and frequency of any AEs of special interest (AEOSI), such as pulmonary, gastrointestinal, cuteaneous, renal, hepatic, pancreatic, endocrine, infusion-related, or hypersensitivity|Incidence of all high-grade (Grade 3 and higher) select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Time to overall survival (OS)|Investigator assessed objective response rate (ORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	1215	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-172|2014-001286-28	October 7, 2014	January 30, 2019	January 30, 2019	June 5, 2014	null	July 13, 2018	Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, St. Polten, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Az Groeninge, Kortrijk, Belgium|Local Institution, Leuven, Belgium|Chu De Liege, Liege, Belgium|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Jyvaskyla, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Luebeck, Schleswig-holstein, Germany|Local Institution, Augsburg, Germany|Local Institution, Bochum, Germany|Local Institution, Buxtehude, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dessau, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Freiburg, Germany|Local Institution, Gera, Germany|Local Institution, Giessen, Germany|Local Institution, Goettingen, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Jena, Germany|Local Institution, Kassel, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Marburg, Germany|Local Institution, Minden, Germany|Local Institution, Muenster, Germany|Local Institution, Munchen, Germany|Local Institution, Munich, Germany|Local Institution, Munster, Germany|Local Institution, Nuernberg, Germany|Local Institution, Quedlinburg, Germany|Local Institution, Recklinghausen, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Traunstein, Germany|Local Institution, Tubingen, Germany|Local Institution, Wurzbug, Germany|Local Institution, Heraklion, Creta, Greece|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Pecs, Hungary|Local Institution, Szegedi, Hungary|Local Institution, Szombathely, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Waterford, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Palermo, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Luxembourg, Luxembourg|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Sittard-Geleen, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Alesund, Norway|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Bucharest, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Albacete, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Bilbao, Spain|Local Institution, Granada, Spain|Local Institution, Las Palmas de Gran Canaria, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Hospital De Madrid, Norte Sanchinarro, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Oviedo, Spain|Local Institution, Palma de Mallorca, Spain|Local Institution, Salamanca, Spain|Local Institution, San Sebastian, Spain|Comp. H. U. De Santiago, Santiago de Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Toledo, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Basel, Switzerland|Local Institution, Bellinzona, Switzerland|Local Institution, Bern, Switzerland|Local Institution, Chur, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Birmingham, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Essex, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Surrey, United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02156804
82	NCT02576509	An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma		Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Sorafenib	Overall Survival (OS)|Progression-Free Survival (PFS)|Programmed death (PD)-L1 expression|Overall Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	726	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-459	November 25, 2015	June 9, 2019	July 14, 2020	October 15, 2015	null	November 6, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of California San Francisco, San Francisco, California, United States|University Of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitaetsklinikum Graz, Graz, Austria|AKH Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Lyon, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 13, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse Cedex 9, France|Charite Campus Virchow Klinikum, Berlin, Germany|Kliniken Essen-Mitte/Huyssens-Stift, Essen, Germany|Klinikum Der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Grosshadern, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Tel Aviv, Israel|Ospedale G.Rummo, Benevento, Italy|Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy|Istituto Nazionale Per Lo Studio E La Cura, Milano, Italy|Local Institution, Orbassano, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Chiba City, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Saga-shi, Saga, Japan|Local Institution, Chiyoda-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Hwasun-gun, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Oddzial Onkologii, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Alicante, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Goteborg, Sweden|Local Institution, Stockholm, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT02576509
83	NCT02038946	Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)		Active, not recruiting	Has Results	Lymphoma	Drug: Nivolumab	Overall Response Rate (ORR) as Determined by IRRC|Duration of Response (DOR) Based on IRRC Assessments|Complete Remission Rate (CRR) Based on IRRC Assessment|Partial Remission (PR) Rate Based on IRRC Assessment|Progression Free Survival (PFS) Based on IRRC Assessment|Overall Response Rate (ORR) Based on Investigator Assessments	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	116	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-140|2013-003645-42	March 6, 2014	May 17, 2017	April 8, 2019	January 17, 2014	June 12, 2018	November 14, 2018	Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Woodville, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Des Saarlandes, Homburg, Germany|Local Institution, Regensburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Oslo, Norway|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital Duran I Reynals, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02038946/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02038946
84	NCT02038933	Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)		Active, not recruiting	Has Results	Lymphoma. Non-Hodgkin	Drug: Nivolumab	Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment|Duration of Response (DOR)|Complete Remission Rate|Duration of Complete Remission|Rate of Partial Remission|Duration of Partial Remission|Progression Free Survival|Objective Response Rate (ORR) Per Investigator Assessment	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	161	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-139|2013-003621-28	February 10, 2014	April 8, 2016	April 1, 2019	January 17, 2014	May 30, 2017	October 24, 2018	Mayo Clinic Arizona, Phoenix, Arizona, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|Winship Cancer Center, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Woodville, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, B-leuven, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Creteil, France|Local Institution, Montpellier Cedex 05, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Homburg, Germany|Local Institution, Ulm, Germany|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Roma, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Hospitalet Llobregat- Barcelona, Spain|Local Institution, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Withington, Manchester, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02038933
85	NCT03598816	PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma	PIVOT-RCC	Not yet recruiting	No Results Available	Renal Cell Carcinoma	Drug: Durvalumab|Drug: Tremelimumab|Device: TDS-IM System|Biological: Neoantigen DNA Vaccine|Procedure: Research blood draw	Safety of the combination of durvalumab & tremelimumab with or without neoantigen DNA vaccine when given to patients with renal cell carcinoma as measured by defined as the percentage of patients with adverse events of grade 3 or higher|Response rate in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine by RECIST 1.1 as measured by percentage of patients with radiographic complete response or partial response|Rate of progression-free survival (PFS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine|Rate of overall survival (OS) in patients with renal cell carcinoma treated with durvalumab and tremelimumab with or without neoantigen DNA vaccine	Washington University School of Medicine|MedImmune LLC	All	18 Years and older   (Adult, Older Adult)	Phase 2	48	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-x172	February 28, 2019	May 31, 2021	November 30, 2021	July 25, 2018	null	November 21, 2018	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03598816
86	NCT02941744	A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases	ipniv	Recruiting	No Results Available	Stage IIIC Skin Melanoma|Stage IV Skin Melanoma	Drug: nivolumab|Drug: ipilimumab	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|to measure t cell repertoire before and after treatment with low dose ipilimumab and nivolumab with immunoseq.	Universitair Ziekenhuis Brussel	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	6	Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2016-BN-001	March 2016	March 2018	March 2019	October 21, 2016	null	May 25, 2017	UZ Brussel, Jette, Brabant, Belgium		https://ClinicalTrials.gov/show/NCT02941744
87	NCT03084640	Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma		Recruiting	No Results Available	Malignant Melanoma	Drug: CMP-001|Drug: Pembrolizumab	Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Administered SC and Given in Combination With Pembrolizumab|Part 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part 1 Dose Escalation and Dose Expansion: Number of Participants With TEAEs|Part 1 Dose Escalation and Dose Expansion, and Part 2: Oral Temperature|Part 1 Dose Escalation and Dose Expansion, and Part 2: Respiratory Rate|Part 1 Dose Escalation and Dose Expansion, and Part 2: Systolic and Diastolic Blood Pressure|Part 1 Dose Escalation and Dose Expansion, and Part 2: Body Weight|Part 1 Dose Escalation and Dose Expansion, and Part 2: Body Mass Index (BMI)|Part 1 Dose Escalation and Dose Expansion, and Part 2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters|Part 1 Dose Escalation and Dose Expansion, and Part 2: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters|Part 1 Dose Escalation: Concentration of Chemokine IP-10|Part 1 and Part 2: Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Using Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2: Best Overall Response (BOR) Rate (Percentage of Participants With Best Objective Response of CR or PR) as per RECIST Version 1.1 Using CT or MRI Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2: Time to Response (TTR) as per RECIST Version 1.1 Using CT or MRI Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2: Duration of Response (DOR) as per RECIST Version 1.1 Using CT or MRI Scans	Checkmate Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 1	76	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CMP-001-002	May 4, 2017	October 2019	December 2019	March 21, 2017	null	November 14, 2018	University of California, Los Angeles, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Pittsburgh Medical Center - Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03084640
88	NCT02680184	Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy		Recruiting	No Results Available	Melanoma	Drug: CMP-001|Drug: Pembrolizumab	Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Given in Combination With Pembrolizumab|Part 2 Monotherapy: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part 1 Dose Escalation and Dose Expansion: Number of Participants With TEAEs|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Oral Temperature|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Respiratory Rate|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Systolic and Diastolic Blood Pressure|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Body Weight|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Body Mass Index (BMI)|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters|Part 1 Dose Escalation: Concentration of Chemokine IP-10|Part 1 and Part 2: Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Using Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Progression-Free Survival (PFS) as per RECIST Version 1.1 Using CT or MRI Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Best Overall Response (BOR) Rate (Percentage of Participants With Best Objective Response of CR or PR) as per RECIST Version 1.1 Using CT or MRI Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Time to Response (TTR) as per RECIST Version 1.1 Using CT or MRI Scans|Part 1 Dose Escalation and Dose Expansion, and Part 2 Monotherapy: Duration of Response (DOR) as per RECIST Version 1.1 Using CT or MRI Scans	Checkmate Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 1	144	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CMP-001-001	March 2016	June 2019	November 2019	February 11, 2016	null	October 30, 2018	Banner MD Anderson Cancer Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of California, Los Angeles, Los Angeles, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Georgetown, Washington, District of Columbia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|West Virginia University, Morgantown, West Virginia, United States		https://ClinicalTrials.gov/show/NCT02680184
